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Abstract
Enacyloxin is a natural product from Burkholderia ambifaria that exhibits an-
timicrobial activity against the multi-drug resistant pathogen Acinetobacter bau-
mannii. The biosynthesis of enacyloxin involves a hybrid modular polyketide
synthase (PKS)-nonribosomal peptide synthetase, performing sequential thiol-
template catalysis. The process of chain release encompasses an unusual domain
architecture that includes an acyl carrier protein domain, a non-elongating ke-
tosynthase domain, a peptidyl carrier protein (PCP) domain and a standalone
condensation (C) domain. Specific protein-protein interactions have been shown
to facilitate chain release, by the identification, and characterisation, of a pair of
communication-mediating domains across a PCP-C protein boundary. This class
of communication-mediating domains was also identified within other biosyn-
thetic pathways using a hidden Markov model, which demonstrates the widespread
occurrence of this type of intermolecular interaction. A hybrid intermolecular in-
teraction was formed using non-native communication-mediating domains from
watasemycin and enacyloxin biosynthetic pathways, which demonstrate their in-
herent compatibility.
A search for enacyloxin analogues revealed a homologous biosynthetic gene
cluster within rhizosphere-associated Vibrio rhizosphaerae. A novel enacyloxin
analogue, vibroxin, was isolated for characterisation by high-resolution mass
spectrometry and nuclear magnetic resonance spectroscopy. The relative stere-
ochemistry of a cyclohexane moiety is consistent with that of enacyloxin, and
the assignment of other stereo-centers are proposed from ketoreductase domains.
Analysis of PKS proteins revealed a methyltransferase domain within the loading
module, where isotopic feeding experiments support a dimethylated starter unit.
Fragments of acyltransferase (AT) domains, identified within PKS proteins, in-
dicate a transition state between a cis-AT PKS and a trans-AT PKS. Vibroxin
exhibits potent antimicrobial activity against Acinetobacter baumannii, demon-
strating the benefit of the genomics-driven approach for the discovery of novel
bioactive compounds.
xi
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Chapter 1
Introduction
1.1 Natural products
The discovery of novel antibiotics over the last 50 years has declined dramat-
ically, whilst multidrug-resistant bacterial pathogens, like methicillin-resistant
Staphylococcus aureus1 (MRSA), Pseudomonas aeruginosa,2 and Acinetobacter
baumannii3 have proliferated rapidly. This constitutes an ever-growing health-
care challenge, and is recognised as a global threat.4 Without the development of
novel antibiotics, and regulated prescription, many standard medical treatments,
that we depend on, will fail. Currently, the majority of clinically important an-
timicrobial agents are derived from bacterial natural products.5 The discovery of
novel natural products will provide important drug-leads, to combat the rise of
multidrug-resistant bacteria. A detailed understanding of natural product biosyn-
thesis can provide motivation for rational mutasynthetic approaches to develop
drug-leads, or to engineer biosynthetic pathways, developing novel compounds.
1.2 Biosynthesis using megasynthases
Many natural products are biosynthesised via enzymatic assembly lines. Similar
to product assembly lines, where each worker has a specific component to se-
quentially add to a product, microorganisms contain enzymes, acting as workers,
1
which produce an antibiotic product. These enzymes recruit chemical building
blocks (commonly malonate from malonyl CoA, or an amino acid), append them
to the product, and pass the product to the following enzyme in a defined or-
der, to manufacture an antibiotic. A thorough understanding of natural product
assembly provides opportunities to venture towards rationally engineering these
processes, to combat the challenge of multi-drug resistant microbial pathogens.
Two foundational classes of natural products are derived from the acetate
pathway: fatty acids and polyketides, produced respectively by fatty acid syn-
thases (FASs), and polyketide synthases (PKSs). Fatty acid synthesis is funda-
mental to the production of energy and cell structure, which designates it as a
member of primary metabolism, being essential for life. FAS I is a dimeric multi-
enzyme protein6 that sequentially synthesises aliphatic acids. Each enzymatic
domain from FAS is well-characterised both structurally and biochemically, from
a diverse range of organisms.6–9 Akin to FAS, PKSs can also resemble multi-
enzyme proteins10 or can be composed of independent enzymes acting in succes-
sion11 or iteratively.12 Alternatively, natural products that are synthesised from
amino acids, can be produced by a nonribosomal peptide synthetase (NRPS).
1.3 Domain organisation and function
1.3.1 PKS domains
Type 1 PKSs are large, highly modular proteins, where enzymatic domains catal-
yse sequential reactions on carrier protein-bound intermediates.10 A prerequisite
for PKS biosynthesis is the post-translational modification of apo-acyl carrier
proteins (ACPs) to their holo form, using a phosphopantetheinyltransferase (PP-
Tase) as shown in Fig. 1.1a. Archetypical PKSs load malonyl or methylmalonyl
extender units, based on the substrate specificity of acyl transferase (AT) do-
mains, onto a downstream holo-ACP domain (Fig. 1.1bi). Ketosynthase (KS)
domains act to elongate the polyketide by catalysing decarboxylative Claisen con-
2
densation of (methyl) malonyl-ACP and the upstream thioester (Fig. 1.1bii). In
the case of an extender unit resulting in malonyl-ACP, methyltransferase (MT)
domains can methylate the substrate after condensation (Fig. 1.1biii).13 Addi-
tional domains can act on the growing natural product, resulting in changes at the
  position; reduction by a ketoreductase (KR) domain (Fig. 1.1biv), subsequent
dehydration by a dehydratase (DH) domain (Fig. 1.1bv), and enoyl reduction by
an enoyl reductase (ER) domain (Fig. 1.1bvi). Chain release, from the PKS, is
typically accomplished by a thioesterase (TE) domain, which can also facilitate
macrocyclisation.
1.3.2 NRPS domains
The typical architecture of an NRPS module includes an adenylation (A) domain,
which determines the amino acid specificity, and facilitates amino acid loading
onto a peptidyl carrier protein (PCP) domain, through an ATP-dependent pro-
cess. A condensation (C) domain condenses amino acids, to form an amide bond
between the thioester of the growing chain from the previous module, and the
amino group of the amino acid-PCP from its own module. Additional enzymes
may act within an NRPS, modifying loaded amino acids. The most common
of which is the epimerization (E) domain, that epimerizes at the ↵ position of
the proximal PCP-bound amino acid. NRPSs can also form hybrid biosynthetic
pathways with PKSs, either as distinct NRPS and PKS proteins, or as chimeric
proteins.
1.3.3 PKS/NRPS product prediction
The sequential and combinatorial nature of PKSs and NRPSs allows the collec-
tion of domains into modules, corresponding to one round of chain elongation
of a carrier protein-tethered intermediate. The nature of the elongation unit is
determined by the specificity of AT domains in PKSs, and A domains in NRPS.
For each type of loading domain, the substrate can be predicted based upon
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Figure 1.1: a) Conversion of apo-ACP to holo-ACP, b) mechanisms of PKS
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ketoreductase, v) dehydratase, vi) enoyl reductase.
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amino acids within their active site.14,15 The auxiliary KR domain, governs the
stereochemistry of the  -OH (and ↵-Me if present) at a thioester. The stere-
ospecificity of any given KR domain can also be predicted based on active site
amino acids.16 For PKS modules containing a trio of KR, DH, and ER domains,
the resulting stereochemistry of an ↵-Me (if present) can be putatively assigned,
based on the presence of a conserved tyrosine amino acid17 within the ER domain.
Together, the predictions of enzyme specificity, classification, and their sequen-
tial occurrence within modules, provides a useful prediction of the core molecular
structure of a PKS, or NRPS, derived natural product.
1.4 Docking and communication-mediating do-
mains
The genetic organisation of PKS and NRPS genes typically adhere to a ‘colin-
earity rule’, whereby genes are arranged in agreement with the direction of the
thiol-template stages of a biosynthetic pathway. This biosynthetic order needs to
be maintained after translation, to ensure that a particular biosynthetic route is
followed. Each multi-enzymatic protein must selectively interact with an enzyme
corresponding to the subsequent stage of biosynthesis, passing a chemical inter-
mediate, whilst avoiding other enzymes within any given biosynthetic pathway. A
justification for thiol-template biosynthetic sequential order has been identified,
in part, in the form of N- and C-terminal docking domains (dd) in PKSs, and
communication-mediating (COM) domains in NRPSs.
1.4.1 Structures of docking and COM domains
To date, docking domains and COM domains have been structurally characterised
from the biosynthetic pathways of curacin,18 erythromycin,19 pikromycin,20 vir-
giniamycin,21 macrolactin,22 tubulysin,23 surfactin24 (Fig. 1.2), and enacyloxin
(chapter 2). N-terminal docking domains, found at ACP-KS module bound-
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aries, typically form a coiled-coil structure. The C-terminal binding partner also
consists of one, or two, helices that bind across the dimeric interface. Creat-
ing hybrid pairs of docking domains, and mutants have revealed indications of
docking domain selectivity, via key electrostatic interactions.18 The selectivity of
docking domains, is most apparent in a study that measures binding between
each docking domain from erythromycin PKS and pikromycin PKS. It shows
that the binding a nity of native docking domain pairs interact with binding
a nities near 100 µm, whereas no binding was observed with non-native pairings
of docking domains.20 Interestingly, the addition of an adjacent KS domain has
been reported to provide a twofold increase in the a nity of the intermolecular
interaction, and addition of a whole module provides a ninefold increase.20
KS KS
CPCP
EryAI-EryAII
KS
CP
KS
CP
CurK-CurL
KS
CP
KS
CP
CurG-CurH
(SrfB)-SrfCTubCMlnE
CEKR
KS
CP
KS
CP
PikAIII-PikAIV
CKSCP
VirA-VirFG
Figure 1.2: Structures of docking domains and COM domains from the following
PDB coordinates: 4MYY, 4MYZ, 1PZR, 3F5H, 2N5D, 5D2E (single protomer
shown), 2JUG (single protomer shown from a dimeric species), 2VSQ (mimic of
a COM domain interaction).
Another type of docking domain structure, found across split-module PKS
6
boundaries, possesses a helix-turn-helix structure (e.g. VirA-VirFG and MlnE),
which forms a four-helical bundle in its heterodimeric complex. This class of
docking domain appears across split modules, with di↵erent types of PKS en-
zymes found adjacently. The low micromolar dissociation constant measured for
this class of docking domain, support the capability of mediating the association
of neighbouring domains.22 Truncation and swapping docking domains show their
importance for forming protein complexes, and their pairwise portability.22
A structure of an N-terminal COM domain is reported from SrfC within the
surfactin NRPS, which forms a  -sheet structure with the adjacent condensation
domain. A mimic of the corresponding C-terminal interaction partner, within
SrfB, forms an ↵-helix that makes contacts with the N-terminal COM domain,
as well as the condensation domain. At a PCP-C protein boundary (TubB-
TubC from tubulysin NRPS), an isolated N-terminal interaction domain was
structurally characterised, which revealed a distinctively di↵erent class of COM
domain (herein referred to as ‘type 2’) exhibiting a ↵  ↵↵ fold.
1.5 NMR characterisation of protein domains
Small protein domains from PKSs and NRPSs are ideal candidates for structural
characterisation by protein NMR spectroscopy. Docking domains,19,21 COM do-
mains,23 and carrier proteins,25 represent types of small biosynthetic protein do-
mains that have been structurally characterised by NMR. Carrier proteins display
inherent conformational flexibility, making them less desirable for other common
biophysical methods, such as X-ray crystallography. Protein NMR spectroscopy
can uncover atom specific details of protein domains, describing protein interac-
tions in solution, by monitoring changes in the electromagnetic environment of
atoms during a domain-domain interaction. This can provide a molecular-level
description of significant interactions, during the sequential stages of enacyloxin
chain release.
Protein NMR spectroscopy typically relies upon observing 1H, 15N and 13C
7
nuclei. To improve sensitivity and enable the use of multidimensional experi-
ments, proteins are often isotopically labelled with 15N and 13C isotopes. One
of the most frequently used solution NMR experiments is the two-dimensional
1H-15N heteronuclear single quantum coherence spectroscopy (HSQC) sequence,
where each 1H-15N correlation signal is assigned to a specific amino acid residue
in the primary sequence of the protein. The HSQC spectrum provides a snapshot
of the electromagnetic environment for each 1H-15N bond within a protein, in
the form of chemical shift values. Since the chemical shifts depend on their local
environment, perturbations, or changes in cross peak intensity, in the presence of
a binding partner can be used to map interaction sites with other proteins.
1.6 Enacyloxin PKS-NRPS
PKSs and NRPSs have been identified in bacteria, fungi, plants and some ani-
mal genomes.26,27 Recently, the proteobacteria Burkholderia has been identified
as a promising candidate for the discovery of bioactive compounds, based on
the genome-guided discovery of natural product biosynthetic gene clusters.28 The
Burkholderia genus consists of over forty Gram-negative species that occupy re-
markably diverse ecological niches, through the production of secondary metabo-
lites.29 A group of seventeen closely related Gram-negative bacteria, so-called
Burkholderia cepacia complex (Bcc), are known to demonstrate biopesticidal in-
teractions against fungal diseases in plants,30 biodegrade pollutants,31,32 and have
the ability to cause devastating lung infections in individuals with cystic fibro-
sis.33 Screening a large collection of Bcc strains has identified a strong activity
against Acinetobacter baumannii, which exhibits resistance to most antibiotics
and is one of the most problematic pathogens in healthcare institutions globally.
This antimicrobial activity has been identified from Bukholderia ambifaria, and
the anti-Gram-negative activity was mapped to a biosynthetic gene cluster using
transposon mutagenesis.34 Purification and structure elucidation of the metabolic
products identified them as the antibiotic enacyloxin IIa and iso-enacyloxin IIa.34
8
The proposed biosynthetic pathway for enacyloxin IIa is outlined in Fig. 1.3.
It consists of a large modular PKS, NRPS domains, a pathway for a shiki-
mate derived compound, and tailoring enzymes. The loading module in protein
Bamb 5925 consists of a MT domain, a GNAT domain (malonyl transferase/de-
carboxylase from the Gcn5 histone acyltransferase family) and an ACP domain,
which initiates polyketide assembly with a propionyl starter moiety. Modular ex-
tension continues in a largely sequential manner for ten rounds of chain extension
from PKS proteins belonging to the cis-AT PKS phylogeny, despite many of these
modules lacking an AT domain within their modules. Polyketide chain release is
preceded by a PKS module within Bamb 5919, belonging to the trans-AT PKS
phylogeny, which does not perform chain elongation. The natural product inter-
mediate is proposed to be passed from the ACP of Bamb 5919, to the adjacent
non-elongating ketosynthase (KS0), that lacks the necessary catalytic histidine
for chain elongation. The chain transfer continues from the KS0 domain to a
PCP domain within Bamb 5917, where specific protein-protein interactions are
postulated to contribute to the directionality of this process. Chain release is ac-
complished by the condensation of the 3’-hydroxyl group of a shikimate derived
dihydroxy-cyclohexane carboxylic acid (DHCCA), with the PCP-bound polyke-
tide. The biosynthetic pathway for the DHCCA compound includes the proteins
Bamb 5912 Bamb 5913, Bamb 5914, Bamb 5916 and Bamb 5918. The conden-
sation reaction is catalysed by an NRPS-like C domain within Bamb 5915. The
released intermediate then becomes the substrate for a series of tailoring enzymes
(Bamb 5927, Bamb 5928, Bamb 5931, Bamb 5930 and Bamb 5932).
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1.7 Objectives
1.7.1 Objective I
The primary objective is to elucidate the biophysical basis for the unusual chain
release mechanism from the enacyloxin biosynthetic pathway. This process in-
volves two surplus enzymes, in terms of biochemistry, so it is proposed that a se-
ries of compatible interactions take place between ACP, KS0, PCP and C protein
domains. This could explain the necessity for this unusual domain architecture.
Elucidating the molecular basis for product release from the enacyloxin pathway,
will facilitate the application of this unusual enzymology to synthetic biology
approaches, for novel antibiotic production. A major challenge for engineering
biosynthetic pathways is developing a molecular-level understanding of domain-
domain and protein-protein interactions to faciliate e cient catalysis. The de-
scription of interactions during enacyloxin chain release could describe rules of
interactions that could facilitate bioengineering novel biosynthetic pathways, and
describe unidentified features from characterised biosynthetic pathways.
1.7.2 Objective II
The secondary objective is to search for enacyloxin analogues, exploit any bioac-
tive properties and to investigate the biosynthesis of enacyloxin analogues. A
genomics-driven approach will be used to extensively search databases of se-
quenced organisms as experimental leads. Resulting organisms that contain com-
ponents related to the enacyloxin biosynthetic gene cluster, will be acquired,
cultured and their metabolic profile will be surveyed for the production of enacy-
loxin analogues. The structure, spectrum of activity, and biosynthetic pathway
of any enacyloxin-analogues will be investigated. Any beneficial bioactivity of
enacyloxin analogues could provide promising drug-leads, for chemical synthesis
or mutasynthesis.
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1.8 Synopsis
This body of work encompasses three result chapters on the theme of the biosyn-
thesis of enacyloxins. Chapter 2 probes an unusual chain release process during
the biosynthesis of enacyloxin, where specific protein-protein interactions are pro-
posed to facilitate biosynthesis. Investigating protein interaction by NMR leads
to the discovery of an interaction site at the C-terminus of a PCP domain. A
crystal structure of the condensing enzyme revealed an additional N-terminal
communication-mediating (COM) domain. Together, this provided a full ac-
count of the intermolecular interaction during chain release between PCP and
C domains. Following the discovery of the COM interaction within the enacy-
loxin biosynthetic pathway, an HMM was developed to search for similar motifs
within other biosynthetic pathways (chapter 3). Many biosynthetic pathways
were identified using this HMM, and a hybrid COM interaction was investigated
at a non-native COM boundary from watasemycin NRPS and enacyloxin PKS-
NRPS. Other types of docking domains were also investigated using HMMs, which
led to the identification of a novel KS-DH protein boundary feature.
The discovery of an enacyloxin analogue is described in chapter 4. A genome-
mining approach revealed an enacyloxin-like biosynthetic gene cluster within Vib-
rio rhizosphaerae. The production of an enacyloxin analogue, referred to as vi-
broxin, was purified from extracts of solid cultures, and characterised. Some
of the di↵erences between the molecular structures of vibroxin and enacyloxin
could be predicted from the di↵erences in biosynthetic gene clusters. One sig-
nificant di↵erence between enacyloxin and vibroxin is a dimethylation of the
starter unit during vibroxin biosynthesis, which was investigated by isotope feed-
ing experiments. Rigorous inspection of the PKS proteins, revealed fragments of
AT domains, suggesting intermediate stages between cis-acting AT domains and
trans-acting AT domains. The spectrum of activity of vibroxin is tested against
a set of pathogens, demonstrating its antibiotic potential.
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Chapter 2
Enacyloxin PKS-NRPS chain
release
2.1 Chain release process
During the biosynthesis of polyketides and non-ribosomal peptides, chain release
is ordinarily accomplished by a TE domain. This domain is dedicated to the
hydrolysis of the final thiol-bound intermediate, and often mediates macrocycli-
sation. In contrast, within the enacyloxin biosynthetic pathway, four enzymes
are involved in the formation of an ester bond during chain release. This unusual
system includes an ACP domain, a non-elongating KS domain (KS0), a PCP
domain and a stand-alone C domain. The KS0 domain lacks a catalytic histidine
residue involved in the mechanism for chain elongation. Thus, the KS0 domain
is proposed to act as an adapter between ACP and PCP domains, acting as a
trans-acylase (TA), passing the polyketide intermediate from the ACP domain
to the PCP domain. Subsequently, the catalytic C domain is then proposed to
selectively attack the 3’-OH of dihydroxy-cyclohexane carboxylic acid (DHCCA),
which then forms an ester with the PCP-bound polyketide (Fig. 2.1a). However,
the C domain has also been shown to accept a number of other intermediates
within the DHCCA biosynthetic pathway, including shikimate.35 (10R,30R,40S)-
13
DHCCA does not appear to be a substrate for the C domain, but (10S,30R,40S)-
DHCCA is accepted by the C domain.35. For the remainder of this thesis,
the substrate of the C domain will be referred to as (10S,30R,40S)-DHCCA, or
shikimate, where stated. One alternative pathway describes the condensation
of (10S,30R,40S)-DHCCA with the ACP-bound polyketide, instead of the PCP-
bound polyketide (Fig. 2.1b). However, previous work has shown that in vitro
assays with acetyl-ACP, (10S,30R,40S)-DHCCA and the C domain do not perform
catalysis.36 It is proposed that specific domain interactions play an important role
in this unusual chain release process, requiring four enzymes to produce one ester
bond. The biophysical basis of such specific interactions was investigated, using
a range of biophysical techniques.
ACP PCP
SH SSH
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O
R OH
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OHO
His
H
C0
OH
O
OHO
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O
OH OH OH OH
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H
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a
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Figure 2.1: Stages preceding chain release in enacyloxin PKS-NRPS. a) The
proposed chain release pathway, b) an equivalent biosynthetic pathway without
KS0 and PCP domains.
2.2 Protein NMR spectroscopy
2.2.1 Sample preparation
To uncover specific details of the protein-protein interactions the domains in-
volved in the chain release process in enaclyoxin PKS: ACP (encoded by gene
14
Bamb 5919), KS0 (encoded by gene Bamb 5919), PCP (encoded by gene Bamb 5917)
and C (encoded by gene Bamb 5915) were reconstituted in vitro with N-terminal
His6-tags to facilitate purification. For the reminder of Chapter 2 and for the
sake of simplicity the designations ACP, PCP, C and KS0 will refer to the above
mentioned constructs unless specified otherwise.
In order to facilitate NMR studies and whenever required, 15N and 13C were in-
corporated in proteins by using isotopically labeled precursors as the sole sources
of carbon and nitrogen during recombinant overproduction of proteins in E. coli.
Proteins were purified using nickel a nity column. The SDS-PAGE of the pu-
rified domains are presented in Fig. 2.2. Because KS0 and C domains are very
large, and thus challenging for solution NMR (75 and 60 kDa respectively), only
smaller and amenable to solution NMR ACP and PCP domain where isotopically
labelled and observed in 15N and 13C-filtered experiments. For protein-protein
interaction experiments, carrier proteins were uniformly isotopically labelled with
15N (i.e. [U-15N]PCP and [U-15N]ACP), and the larger domains, KS0 and C, were
not isotopically enriched.
75	kDa
60	kDa
C
KS0
15	kDa
PCP
22	kDa
ACP
14	kDa
Figure 2.2: SDS-PAGE of purified domains from enacyloxin PKS.
2.2.2 Carrier protein interactions with partner domains
Protein-protein interactions, or the formation of protein-protein complexes, can
be characterised by following changes in 2D 1H-15N HSQC spectra of uniformly
15N-labelled carrier protein upon addition of a larger domain, e.g. natural abun-
dance C or KS0 domains (Fig. 2.3). In the case of fast chemical exchange the
15
changes of positions (or chemical shifts) of the sites involved in binding inform on
the interaction. In the case of slow chemical exchange the interaction manifests
as a decrease of the intensity of the peak for free site and increase of intensity of
the peak for the bound site as a function of interacting partner concentration. As
the size of the complex increases the decrease in the overall rotational di↵usion
correlation time leads to improvement of transverse relaxation and associated
line broadening. For very large complexes, as it is in our case, the signals of the
carrier protein in the complex may become broadened beyond detection.
pH 6-7.5Temp. 15-25 oC
a b
c d
Figure 2.3: 1H-15N HSQC spectra of carrier proteins in isolation (blue), and
with the addition of a partner domain at a 1:1 ratio (red). a) ACP-KS0, b)
PCP-KS0, c) PCP-C, d) ACP-C.
Within the HSQC spectra of protein complexes ACP-KS0, PCP-KS0 and
PCP-C (Fig 2.3a-c), there are significant changes in the HSQC spectra of carrier
proteins following the addition of a larger partner domain. This indicates an in-
teraction between them. On the contrary, the ACP-C complex HSQC spectrum
shows no significant changes when compared with those observed for the other
domain-domain experiments (Fig 2.3d). This di↵erence in behaviour of PCP and
ACP suggests that the ACP lacks a compatible interaction site for the C domain.
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The residue assignment of PCP was then undertaken, to uncover the specific
details of the interaction site on PCP.
2.2.3 Residue assignment of PCP
The bu↵er conditions for NMR samples were screened for stability of PCP, includ-
ing changes to pH (Appendix Fig. 7.1, 7.2) and temperature (Appendix Fig. 7.3,
7.4). A suite of three-dimensional NMR experiments could then be performed
(Section 5.4.2), to sequentially deduce the assignment of [U-13C,15N]PCP. The
backbone assignment of PCP was achieved for 96% of backbone amides (Fig. 2.4,
Appendix Table 7.1), excluding the N-terminal purification tag. The dispersion
of the hydrogen chemical shifts are characteristic of a well-folded protein, but the
random coil deviations, proximal to the C-terminus, are indicative of an unstruc-
tured peptide, with a high degree of disorder (Fig. 2.5).
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Figure 2.4: HSQC of PCP where the amide assignment is listed in Appendix
Table 7.1.
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Figure 2.5: Random coil chemical shift deviations for PCP based on the di↵er-
ence in C↵i and C i chemical shift values for each residue, i. Predicted secondary
structure is represented above the bar chart, where bold lines indicate helices and
the active site serine residue is identified with an arrow.
2.2.4 C-terminal interaction site
The aforementioned HSQC spectra, that monitor interactions between PCP and
C domains, display peak broadening, where the C-terminal region displays the
most intense signals, even with a relatively high concentration of the C domain.
The high intensities of these correlations correspond to a region of the protein
that does not conform to the core helical bundle, observed in other carrier protein
structures. In fact, the chemical shifts of this C-terminal extension are consistent
with an unstructured, or disordered, peptide. This lack of secondary structure
is congruous with the observed high signal intensities. The decay in each amide
correlation signal, during interaction of the PCP and C domain, can be observed
across the PCP protein to identify interaction sites during complex formation. As
well as the core PCP domain, significant changes were observed at the disordered
C-terminus of PCP (Fig. 2.6a-e) from about residue 125 to residue 134, with in-
creased amounts of C domain. This suggests that the C-terminal region is impor-
tant for the complex formation of the PCP and C domains, and consequentially
facilitating ester formation, during chain release. This C-terminal domain, down-
stream of PCP, shall be referred to as a C-terminal communication-mediating
domain (COM2C).
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Figure 2.6: Normalised signal intensities for PCP-COM2C amide HSQC correla-
tions upon titration with natural abundance C domain, for the following C:PCP
ratios: a) 1:16, b) 1:8, c) 1:4, d) 1:2, e) 1:1.
2.3 In vitro bioassays
2.3.1 Construction of mutants
The role of the COM2C domain can be investigated using assays that depend
upon the COM interaction. To evaluate the biochemical importance of the COM
domains, nine amino acids were removed from the C-terminus of PCP-COM2C
to form PCP. This was achieved by site-directed mutagenesis, where a premature
stop codon was substituted on the PCP-COM2C expression plasmid. The trun-
cated protein, PCP, was recombinantly overproduced and purified (Fig. 2.7a).
Mass spectrometry of PCP (Fig. 2.7bi) and PCP-COM2C (Fig. 2.7bii) provide
ions consistent with predicted molecular weights, 14466.3 Da and 13403.1 Da
respectively.
2.3.2 Condensation assay
A condensation assay was developed using: acetyl-PCPs (Bamb 5917), the C do-
main (Bamb 5915), and shikimate, as a mimic of DHCCA (Fig.2.8a). This setup
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Figure 2.7: Truncated mutant PCP. a) SDS-PAGE of PCP, b) MALDI-ToF
spectra of i) PCP truncated mutant, ii) PCP-COM2C .
could be used to verify the role of the COM2 boundary during biosynthesis, in
particular the e↵ect of COM2C . A mimic of the wild-type system, acetyl-PCP-
COM2C with the C domain and shikimate, yielded a product consistent with
acetylated shikimate, monitored by LC-MS. The extracted ion chromatogram cor-
responding to the sodiated adduct of acetylated shikimate displays three species
with di↵erent retention times (Fig.2.8b). This could be due to acetylation of
each of the three hydroxyls on the cyclohexene during condensation, or acetyl
rearrangement thereafter. The truncated mutant PCP was used to replace the
PCP-COM2C protein in the assay, to investigate the biochemical significance of
the COM2C domain. No product formation was observed for assays containing the
COM2C truncated PCP (Fig.2.8bii). The interpretation of this result is that the
breakdown of the COM2C-dependent intermolecular interaction prevents e cient
complex formation, a prerequisite for catalysis in this case. The assay with the
full length PCP-COM2C was then repeated with the addition of a tenfold excess of
COM2C peptide (11 amino acid length chemically synthesised by Insight Biotech-
nologies). From this assay, no product was detected (Fig.2.8biii). Competitive
inhibition of the protein-protein interaction is proposed to account for signifi-
cantly decreasing catalysis upon the addition of supplementary COM2C peptides.
Together these results support the biochemical significance of the COM2C domain
during chain release of enacyloxin.
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Figure 2.8: a) Schematic representation of the condensation assay. b) E.I.C
corresponding to the sodiated adduct of acetylated shikimate for the assay with
the C domain, shikimate and either, i) acetyl-PCP-COM2C , ii) truncated acetyl-
PCP, iii) acetyl-PCP-COM2C with a tenfold excess of COM2C peptide.
2.4 Crystal structure of the condensing enzyme
In order to determine the possible binding site of COM2C , the structure of the
C domain from enacyloxin PKS-NRPS was solved. This was part of a collabora-
tion between the University of Warwick and UC Irvine, which included Timothy
Valentic, Sheryl Tsai, Paulina Sydor, Dean Rea and Vilmos Fu¨lo¨p. This structure
deviates from other NRPS-like C domain structures, by a loop above the active
site, and the addition of an N-terminal domain.
2.4.1 N-terminal appendage
The additional N-terminal domain consists of an ↵  ↵↵ structure, and appears
recurrently within NRPS proteins, typically identified upstream of condensation
or heterocyclisation domains using homology searches and motif finders. An
isolated structure of a homologous domain was solved from tubulysin NRPS23
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(Fig. 2.9a), and its function was proposed to perform an intermolecular interaction
across a protein boundary. Subsequently, this type of domain will be herein
referred to as a ‘type 2’ N-terminal communication mediating (COM2N) domain.
This will distinguish it from ‘type 1’ COM domains, regularly identified between
condensation domain and epimerisation domain boundaries (see Chapter 3 for
further details).37
The crystal structure of COM2N -C from enacyloxin PKS-NRPS, provides the
first structural account of the relative positioning of a COM2N domain, to its
catalytic neighbouring domain (Fig. 2.9b). A short linker allows the COM2N
domain to situate near the C-terminal subdomain of the condensing enzyme,
positioned adjacently to the entrance of the downstream substrate. Amino acids
Thr2 and Tyr51 from the COM2N domain engage in polar contacts with Glu380
and Ser383 from the C domain respectively, which stabilise the localisation of
COM2N .
2.4.2 Loop above the active site
The structure of the C domain contains some variations from other NRPS C do-
main structures, namely between Ser418 and Ser453. Within this region, a loop
extends above the C-terminal subdomain, forming little secondary structure. In
other structures this region typically forms a  -sheet with the N-terminal subdo-
main with additional helical components, displaying an overall more structured
fold. These di↵erences could arise from the isolated nature of this particular con-
densation domain, as its placement di↵ers from the archetypal location within an
NRPS module. Whilst the upstream PCP delivers a polyketide to the accepting
face of the condensing enzyme, access to the donating face is proposed only to
facilitate a relatively small substrate (e.g. DHCCA), not a typical PCP-bound
amino acid.
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Figure 2.9: a) COM2N structure from tubulysin NRPS.23 b) COM2N -C dido-
main structure from enacyloxin PKS-NRPS. Linker between COM2N domain and
C domain is shown in blue. The atypical loop within the C domain is shown in
red.
2.5 Protein-protein complex
A crystal structure of a PCP-E didomain38 (Fig. 2.10a) from gramicidin S NRPS
provides a reference for modelling the PCP-C complex from enacyloxin PKS-
NRPS, as E domains and C domains possess the same overall fold. The PCP
domain from enacyloxin PKS-NRPS was overlayed on the PCP-E structure, and
the COM2N -C domains were aligned to the relative position of the E domain
(Fig. 2.10b).
PCP E PCP C
a b
Figure 2.10: a) PCP-E didomain structure from gramacidin NRPS.38 b) Align-
ment of the COM2N -C domains and PCP from enacyloxin PKS-NRPS to the
relative positions of the PCP-E complex structure.
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Models of the interaction between COM2N and COM2C domains have been
proposed from tubulysin NRPS23 (Fig. 2.11ai) and myxothiazol NRPS39 (Fig. 2.11aii).
Using the structure of COM2N , and the partner interaction site COM2C , a protein-
peptide molecular dynamics simulation was performed to objectively investigate
the COM2C-COM2N domain interaction during the biosynthesis of enacyloxin.
Small amounts of helical propensity were observed for the COM2C peptide during
simulations, but it remained largely devoid of any secondary structure generally.
Four clusters of solutions of the COM2N and COM2C complex are represented
in Fig. 2.11b. Each of the protein-peptide complex models represent clusters
of hundreds of states, where the COM2C peptide samples proximal regions of
the COM2N surface. These solutions may represent a ‘fuzzy’ complex, whereby
degenerate multiplicity exists, as is commonly observed for interaction sites in-
volving disordered peptides.40,41 It is unlikely that the proposed interaction sites
on the COM2N can be simultaneously occupied by the COM2C domain, due to
their relatively large expanse. The COM domain complex solutions provide an
insight into the role of the hydrophobic amino acids on COM2C . There are two
pockets, adjacent to the  -hairpin, that locate the hydrophobic residues (namely
valine and isoleucine) on COM2C .
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Figure 2.11: a) COM2N domain interaction sites (sticks) proposed from i) a
COM2N from tubulysin NRPS,23 ii) a COM2N domain homology model from
myxothiazol NRPS.39 bi-iv) Solutions from simulations of the COM2C domain
(purple, C-terminus represented as sphere) with the COM2N domain from ena-
cyloxin PKS-NRPS.
Coupling the PCP-C model, and the COM2N -COM2C models, provides a rep-
resentation of the entire complex (Fig. 2.12). It describes intermolecular com-
munication, and the interactions of adjacent enzymes responsible for catalytic
activity during enacyloxin chain release. A model solution for the COM domain-
complex was linked to the C-terminus of the core PCP domain by building in
a loop, which was subsequently subjected to energy minimisation. The PCP-
COM2C and COM2N -C complex model describes the proposed interactions, and
a schematic of the states it must accommodate during biosynthesis. After trans-
lation, the intermolecular interactions that are required between the PCP and C
domain, are proposed to be facilitated by a pair of compatible COM domains.
This ensures a particular biosynthetic pathway is followed, and acts to increase
the e↵ective concentration of the PCP domain with respect to the C domain.
Following COM domain interactions, the PCP is proposed to deliver a polyke-
tide intermediate to the C domain, for condensation with a shikimate derived
compound. The holo-PCP domain then needs to leave the C domain so that the
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terminal thiol of holo-PCP can be made acessible, to load another molecule of
the polyketide from the KS0 domain, before redelivery to the C domain for ester
formation with DHCCA.
PCP
accept 
substrate
donate 
substrate
C
COM
interaction
Figure 2.12: Representation of the domain oragnisation of PCP-COM2C and
COM2N -C from enacyloxin PKS-NRPS. COM domains are propsed to direct
intermolecular interactions, where the PCP domain accepts polyketides from the
previous module to donate to the C domain in a recursive manner.
2.6 Conclusion and future work
Protein interactions have been shown to play an important role in the unusual
chain termination process during enacyloxin biosynthesis. Interactions between
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domains have been observed by protein NMR spectroscopy, and are consistent
with the proposed biosynthetic pathway. Biophysical investigation of the chain
release process has uncovered a pair of COM domains, which form specific inter-
molecular interactions across the PCP and C protein boundaries. The residue
assignment of PCP, and PCP-C mixing experiments, led to the identification of a
C-terminal COM domain, exhibiting high levels of disorder. This COM domain
has been shown to be necessary for e cient catalysis, performing a fundamental
intermolecular interaction across a protein-protein boundary.
The structure of the C domain revealed an additional N-terminal COM do-
main, and its position relative to the catalytic C domain. The nature of the COM
domain interaction was simulated, which provided clusters of statistical solutions.
These states were subsequently evaluated based upon the NMR interaction data
with the C-terminal binding partner. However, an experimentally determined
structure of the protein complex, or an experimentally verified description of
the interactions sites on the N-terminal COM domain interface, would provide
additional insight to this particular intermolecular interaction.
The COM domain interaction has led to an updated description of chain re-
lease within enacyloxin biosynthesis, and is proposed to drive complex formation
to facilitate catalysis. This COM domain interaction site allows the quaternary
structure to be maintained, whilst permitting accessibility for the PCP domain
to locate the active sites of both the C domain, and the KS0 domain. Given
the significance of the COM domain interaction within enacyloxin biosynthesis,
further experiments could investigate the exploitation of this interaction to ra-
tionally engineer intermolecular interactions to develop hybrid biosynthetic path-
ways. Furthermore, to test the promiscuity of the enzymes across COM domain
boundaries, creating a chimeric protein of ACP-COM2C (instead of PCP-COM2C)
would present valuable insight to the tolerance of ACP and C domains, and ven-
tures for engineering COM domain intermolecular interactions to biosynthesise
novel chemical entities. In order to discover the prevalence of this form of COM
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domain interaction, new tools could be developed for their annotation within
biosynthetic pathways.
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Chapter 3
Intermolecular docking domains
and communication-mediating
domains
3.1 Identification of docking and COM domains
Given the large number of known PKS and NRPS proteins, docking domains and
COM domains are scarcely identified within them. The development of new tools
to identify these terminal domains will provide a more detailed understanding of
intermolecular interactions within PKSs and NRPSs.
3.1.1 Profile hidden Markov models for dd1 and COM1
Docking domains and COM domains can be identified using profile hidden Markov
models (pHMMs), which consist of a statistical description of a protein family.
Currently, antiSMASH42 utilises two pHMMs that describe N-terminal and C-
terminal docking domains (denoted dd1N and dd1C respectively) and two pHMMs
for COM domains (COM1N and COM1C). The pHMM for COM1N contains a
region that can be considered part of a condensation or cyclisation domain from a
structural perspective (Fig. 3.1). This region of the pHMM leads to a large num-
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ber of results that could be considered potential false positive annotations. As a
consequence, it is commonplace to identify COM1N domains upstream of conden-
sation domains that do not lie at a terminus. The pHMM for the corresponding
binding partner, COM1C , contains a small region that can be attributed to an
epimerisation (E) domain. Despite this, COM1C domains can also be identified
following PCP domains, at PCP and condensation domain protein boundaries
(e.g. VpsA-VpsB from vancomycin NRPS).
C
a b
E
Figure 3.1: HMM logos for a) COM1C and b) COM1N HMMs from antiSMASH.
Analogous to COM domains, docking domains have been identified within a
number of PKSs. These have also been identified using pHMMs for dd1N and
dd1C , corresponding to the N-terminal and C-terminal interaction sites, respec-
tively (Fig. 3.2). The pHMM that includes the dd1C domain, also includes a region
describing an additional dimerisation domain.19 This region has been structurally
characterised from eryAI, and is regularly unidentified within PKS proteins. This
is a limitation of this relatively long pHMM. In contrast, the N-terminal bind-
ing partner, dd1N , more accurately represents the profile of this domain, and is
consistent with a structurally characterised dd1N domain.
a
b
dimerisation
dd1N
dd1C
Figure 3.2: HMM logo for type 1 docking domains used by antiSMASH, a)
C-terminal PKS dd, b) N-terminal PKS dd.
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3.1.2 Novel HMMs for docking domains
A second class of docking domains (dd2) are based on protein termini identified
at ACP and KS boundaries within curacin PKS (CurG-CurH and CurK-CurL).18
These dd2 domains were also reported within 22 other biosynthetic pathways at
ACP and KS protein boundaries.18 This set of N-terminal and C-terminal docking
domains (dd2N and dd2C respectively) was used to build two HMMs (dd2N , dd2C)
to facilitate the identification of these domains.
The dd2N and dd2C HMMs were used to search the MIBiG database43 for
biosynthetic pathways that contain dd2 domains. This revealed a large num-
ber of dd2-containing biosynthetic pathways, which were previously unidenti-
fied. The results include biosynthetic pathways for: anabaenopeptin, ambruticin,
burkholdac, chondrochloren, crocacin, ebelactone, enacyloxin, gephyronic acid,
gulmirecin, leupyrrin, microsclerodermins, nannocystin, nostophycin, pellasoren,
polyoxypeptin, puwainaphycin and spiruchostatin. Each of these examples ex-
hibit class 2 docking domains, which are proposed to facilitate biosynthesis across
ACP and KS boundaries. One exception is nostophycin PKS, where dd2 domains
are not located at protein boundaries of NpnA. Within this protein, dd2N and
dd2C domains are found in between the ACP from module 1 and the KS from
module 2 (Fig. 3.4a). It is clear that docking domains between modules 1 and 2
are not required as they are part of the same protein. These modules may have
originated from separate genes where the dd2 domains would have facilitated
biosynthesis across a protein boundary, but mutations in the stop codon of the
upstream gene could have led to a genetic merger, if the downstream gene was
situated in the same reading frame.
3.1.3 Identifying unknown types of docking domain
Whilst HMMs for docking domains have revealed many biosynthetic pathways
utilising these terminal features, there are many PKS and NRPS proteins where
no docking domains, or COM domains, are identified. In many cases, unanno-
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tated terminal gaps provide motivation to investigate patterns in these terminal
regions, which could uncover novel types of docking domains. To address this,
a database of PKS and NRPS amino acid sequences was curated from charac-
terised biosynthetic pathways, and the termini were extracted to provide a list of
N-terminal and C-terminal amino acid sequences for inspection. These sequences
were analysed for novel motifs (recurring, fixed-length patterns) using MEME.44
The resulting motifs for N-terminal PKS sequences are listed in Fig. 3.3.
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DH
dd1N
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SAT
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dd4N
ACP
ACP
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2.
3.
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6.
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9.
10.
11.
12.
Figure 3.3: Motifs from N-terminal PKS sequences identified using MEME,
listed by statistical significance. Each motif is labelled corresponding to its cat-
alytic domain, or type of docking domain.
The N-terminal motifs could be attributed to docking domains as well as
enzymatic domains that are situated directly at the N-terminus. KS and ACP
domains from type II PKSs were identified by MEME, but did not contain termi-
nal docking domains, as well as KSQ domains involved in loading modules. Other
N-terminal domains include starter-unit:ACP transacylase (SAT) domains from
fungal biosynthetic pathways, and coenzyme A ligase (CAL) domains, conferring
di↵erent forms of PKS loading strategies. The most significant motif was con-
sistent with the well-studied type 1 docking domain, typically observed between
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ACP and KS domains at protein boundaries.
The fourth most significant motif was used to develop a HMM to describe a
docking domain with some similarity to type 2 docking domains (coined dd2N ↵
and dd2C  ). During instances where multiple HMMs identify a docking do-
main within the same amino acid sequence, the highest scoring HMM is chosen.
The dd2N ↵ and dd2C   HMMs identified docking domains from 66 biosynthetic
pathways (Appendix 7.3.1) at protein boundaries between ACP domains and KS
domains. The eighth most significant motif described another pair of putative
docking domains, which were converted into paired HMMs (dd3N and dd3C).
These HMMs were used to identify 22 biosynthetic pathways (Appendix 7.3.2)
from the MIBiG database, which putatively utilise dd3 domains. Most examples
represent boundaries between at ACP and KS domains, but dd3 domains were
also identified at PCP-KS and ACP-C protein boundaries. An example of an
ACP-C boundary is BaeM-BaeN, from bacillaene PKS-NRPS, where a dd3N do-
main was identified at the N-terminus of BaeN (or PksN), illustrated in Fig. 3.4b.
Within the gobichelin biosynthetic pathway, a dd3C domain was identified adja-
cent to a PCP at a PCP-C protein boundary, but no corresponding N-terminal
binding partner was identified next to the condensation domain.
KS
DH
ER
KRKR
PCP AT ACP KS AT ACP
KR
npnA
dd2C-dd2N
KR
KS A PCP
A
dd3N
ACP C
b baeM baeN
......
a
Figure 3.4: Examples of docking domains in unusual locations, a) nostophycin
PKS with dd2 domains in cis b) bacillaene PKS-NRPS showing a PKS-like dd3N
domain adjacent to a condensation domain.
The twelfth motif was identified both at the N- and C-terminus of biosynthetic
genes. The corresponding HMM (dd4) was used to identify this type of docking
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domain from 18 biosynthetic pathways. The predicted structure of dd4 domains
is a helix-turn-helix. When attempting to model the structure of dd4 domains
based on the HMM consensus sequence, a structure of a N-terminal dd4 domain
was found with a ketoreductase from macrolactin biosynthesis (this dd4 domain
was also identified with the dd4 HMM).22 Another structure of dd4 domains was
later characterised from virginiamycin PKS, where a chimeric protein revealed
a chimeric dd4-dd4 interaction over a protein boundary.21 Apart from terminal
d4 domains, three tandem d4 domains were identified within protein CurF from
curacin PKS-NRPS (Fig. 3.5). This stage of biosynthesis has an unusual domain
architecture including three tandem ACPs and four trans-acting enzymes. The
N-terminus of CurF does not seem to accommodate a N-terminal docking domain,
which may suggest that the d4-d4-d4 domains could facilitate biosynthesis across
the protein boundary between CurA and CurF, and play a role in the recruitment
of trans-acting enzymes.
GNAT
KS ATACP ACP ACP
Hal
ACP
d4-d4-d4
ER
KS ATECHACP KS
ECH
HCS
DH
ACP Cy PCPA
curA curB curC curD curE curF
Figure 3.5: Domain organisation of curacin PKS-NRPS displaying tandem d4
domains located between the ER and KS domains.
3.1.4 (2E,4Z)-configuring dehydratase HMM
There were a number of N-terminal DH domains within PKS proteins, reflected in
the seventh motif from MEME. These examples were unusual as the DH domains
were identified directly at the N-terminus of proteins, without any vacancy for an
additional N-terminal docking domain. Reviewing the N-terminal DH domains
from characterised biosynthetic pathways revealed some common features. Each
DH domain was within a module where the ACP-bound intermediate (or an
adjacent ACP-bound intermediate) possessed (2E,4Z)-configured double bonds,
and there was no DH domain within the previous module. The C-terminal region
of the upstream protein was a trans-AT KS domain, but no trans-AT docking
domains were identified. In fact, the region C-terminal to the KS did not contain
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a motif associated with the C-terminus of a KS domain which could position the
downstream module away from the upstream module. This may contribute to the
DH domain acting on the ACP-bound intermediate from the upstream module, or
equivalently, dehydration at the  -OH after chain elongation. In each biosynthetic
pathway, the amino acid sequence to the C-terminus of the KS domain possessed
a relatively low pI.
An HMM was built to describe the N-terminal DH domains that do not pos-
sess a typical docking domain, in the form of an additional terminal appendage.
The intention was to use this model to identify a class of intermolecular interac-
tions between a C-terminal peptide and N-terminal DH domains. However, these
domains were typically identified within modular PKS modules from trans-AT
and cis-AT PKSs, located away from termini (Fig. 3.6). Examples of these DH
domains can be found in the biosynthetic pathways for spirangien, thuggacin
and chivosazole. For chivosazole PKS, the corresponding DH domains that are
not located at the N-terminus, may arise as a consequence of a genetic merger
resulting in two proteins becoming a single protein (as proposed within the nos-
tophycin PKS). For example, in a pathway identified with the N-terminal DH
HMM, the ACP-bound intermediate, within the corresponding module, contains
a (2E,4Z)-configured diene. Within spirangien and thuggacin PKS, the modular
architecture is archetypal of cis-AT modular PKSs (KS-AT-KR-ACP-KS-AT-DH-
KR-ACP). The predicted extension of the ACP-bound intermediate arising from
these two modules would possess a 4-OH, where the stereochemistry is defined by
KR stereospecificity, and a 2E-configured double bond from the module contain-
ing a KR domain and a DH domain. The molecular structures of spirangien and
thuggacin suggest that the modules containing a DH, identified by the aforemen-
tioned HMM, possess an intermediate that contains (2E,4Z)-configured dienes.
This implies that the HMM that was initially developed to describe N-terminal
DH domains, actually encompasses DH domains that could be involved in the
stereospecific configuration of dienes. This could be utilised as a tool to assist
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with the annotation of biosynthetic gene clusters, to predict the configuration of
dienes for uncharacterised polyketides and polyketide-hybrids.
This HMM was also used to predict N-terminal (2E,4Z)-configuring DH do-
mains from biosynthetic pathways for bacillaene, basiliskamide, bongkrekic acid,
chivosazole, di cidin, elansolid, etnangien, kirromycin, macrolactin, sorangicin
and tartrolon (Fig. 3.6). Each of these biosynthetic pathways has an unanno-
tated C-terminal region, which is a putative interaction site on the upstream
protein, at a trans-AT KS and a putative (2E,4Z)-configuring DH boundary. It
is noted that an additional histidine amino acid (predicted to situate within the
active site) is conserved within the proposed (2E,4Z)-configuring DH domains
from trans-AT PKSs, that is not present in other DH domains, which most fre-
quently possess a tyrosine amino acid at the corresponding position. This base
may be involved in the diene synthase mechanism, in particular describing the
additional dehydration event compared with other DH domains.
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Figure 3.6: (2E,4Z)-configuring DH domains from characterised biosynthetic
pathways, identified using the (2E,4Z)-DH HMM.
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3.1.5 Identification of Type 2 COM domains
Two structural representations of a type 2 COM domain have been charac-
terised, TubC from tubulysin NRPS, and Bamb 5915 from enacyloxin PKS-
NRPS. Each of these examples describe intermolecular communication across a
PCP-condensation domain boundary. Despite the relatively large size (90 amino
acids) of a COM2N domain, they cannot be identified using current bioinformatic
methods based on domain conservation (e.g. conserved domain database, Pfam,45
SMART,46 COG,47 TIGRFAM,48 and HMMER.49) To address this, an HMM
was developed using HMMER, which could allow the identification of previously
unidentified COM2N domains (Fig. 3.7b). The atlas PKS/NRPS database50 was
used as a test set of PKS and NRPS proteins, and 218 COM2N domains were
identified. These domains were identified within a range of genera (Appendix
Fig. 7.5), and most frequently from the phyla of proteobacteria, cyanobacteria
and actinobacteria. The interaction partner of the COM2N domain is proposed to
situate at the C-terminus of the previous stage of any biosynthetic pathway. To
inspect these sequences, biosynthetic colinearity is assumed, and the upstream
genes were used to identify the encoded C-terminal sequence. The C-terminal
region was defined as all amino acids from the C-terminus that did not conform
to any other domain, where boundaries were set by PKS and NRPS related pH-
MMs. Alignment of these terminal sequences demonstrates high conservation at
the C-terminus represented in a sequence logo (Fig. 3.7a).51 The most distinctive
conservation are two glutamic acids and leucine forming a EExxL motif within
the terminal six amino acids.
Whilst many COM2N were identified within the atlas PKS/NRPS database,
linking COM2N domains to characterised biosynthetic pathways posed an addi-
tional challenge. Databases that provide a link between PKS and NRPS genes
and their associated natural products assisted with this process (e.g. Cluster-
Mine36052 and MIBiG43), however the majority of COM2N examples were iden-
tified by curating a bespoke database from literature searches of characterised
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Figure 3.7: a) Sequence logo of putative COM2C domains. b) HMM logo for a
COM2N domain.
biosynthetic pathways. Resulting compounds that utilise COM2N domains dur-
ing their proposed biosynthetic pathways are listed in Table. 3.1, along with their
associated bioactivity. The abundance of COM2N domains identified from char-
acterised and cryptic biosynthetic pathways demonstrates their widespread use
across a diverse set of genera.
Table 3.1: Fifty examples of COM2N -containing pathways for bioactive natural
products identified using a hidden Markov model for COM2N domains.
Protein Natural product Species (example) Bioactivity
AerB,J53 aeruginosin Microcystis aeruginosa protease inhibitor54
AjuL55 ajudazol Chondromyces crocatus antifungal56
ApdC,D57 anabaenopeptilide Anabaena sp. 90 protease inhibitor58
AptD59 anabaenopeptin Anabaena sp. 90 protease inhibitor60
BacB61 bacitracin Bacillus subtilis antibiotic62
BarG63 barbamide Lyngbya majuscula molluscicidal64
BlmVII65 bleomycin Streptomyces verticillus anti-tumour66
CmdC67 chondramide Chondromyces crocatus anti-cancer68
SCO768369 coelibactin Streptomyces coelicolor -
ColG70 columbamide Moorea bouillonii cannabinomimetic70
CrpC71 cryptophycin Nostoc sp. ATCC 53789 anti-tumour72
OciC73 cyanopeptin oci Planktothrix agardhii -
McnD,E73 cyanopeptolin Microcystis aeruginosa protease inhibitor58
CtaG74 cystothiazole Cystobacter fuscus antibiotic75
DidC76 didemnin Tistrella mobilis anti-tumour77
DkxG,J78 DKxanthene Myxococcus xanthus antioxidative79
Bamb 591534 enacyloxin Burkholderia ambifaria antibacterial80
EtlC81 entolysin Pseudomonas entomophila hemolytic81
EpoB82 epothilone Sorangium cellulosum anticancer83
EqbG84 equibactin Streptococcus equi -
HctE,F85 hectochlorin Moorea porducens antifungal86
LeuA,E87 leupyrrin Sorangium cellulosum antifungal88
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Table 3.1: (continued)
Protein Natural product Species (example) Bioactivity
LynE,F89 lyngbyabellin Moorea bouillonii anticancer90
MassC91 massetolide Pseudomonas fluorescens antibiotic91
MelG92 melithiazol Melittangium lichenicola antifungal93
MicC,D94 microginin Microcystis aeruginosa treat hypertension95
Psm3b96 micropeptin Microcystis aeruginosa protease inhibitor58
MscI97 microsclerodermins Sorangium cellulosum antifungal98
MxaA99 myxalamid Myxococcus xanthus antibiotic100
MtaD,G101 myxothiazol Stigmatella aurantiaca antibiotic102
NcyE,F103 nannocystin Nannocyctis sp. ST201196 anti-cancer104
NcpA105 nostocyclopeptide Nostoc sp. ATCC53789 anticancer106
NosC107 nostopeptolide Nostoc punctiforme cell-di↵erentiation107
OfaC108 orfamide Pseudomonas protegens insecticide109
PoaC110 poaeamide Pseudomonas poae antifungal110
PuwF111 puwainaphycin Cylindrospermum alatosporum anticancer111
PchF112 pyochelin Pseudomonas aeruginosa antifungal113
DepD114 romidepsin Chromobacterium violaceum anticancer115
SesB116 sessilin Pseudomonas sp. CMR12a anti-fungal117
SyfB118 syringafactin Pseudomonas syringae biosurfactant119
SypB120 syringopeptin Pseudomonas syringae antimicrobial121
TlmVII122 tallysomycin Streptoalloteichus hindustanus anticancer123
TaaB,C124 tolaasin Pseudomonas costantinii mushroom toxin125
TubC23 tubulysin Cystobacter sp. SBCb004 anticancer126
VbxO vibroxin Vibrio rhizosphaerae antibiotic (chapter 4)
ViscC127 viscosin Pseudomonas fluorescens antibiotic128
Sven 0517 watasemycin Streptomyces sp. TP-A0597 antibiotic129
WlpC130 WLIP Pseudomonas putida antibacterial130
XtlC131 xantholysin Pseudomonas putida antimicrobial131
ZbmIX132 zorbamycin Streptomyces flavoviridis antibiotic133
The identification of many bioactive compounds using COM2N domains pro-
vides an opportunity to exploit these features, in a similar manner to early ex-
periments engineering COM1N and COM1C boundaries. This repertoire of natu-
ral products provide an opportunity to biosynthesise hybrid-compounds through
genetic engineering, focused on intermolecular interactions provided by COM2
interfaces. Whilst biosynthetic pathways are regularly divided into modules, cor-
responding to an elongation of a enzyme-bound intermediate, nature has divided
biosynthetic pathways into proteins as biosynthetic components. Protein bound-
aries are regularly observed within an elongation module, where COM (or docking
domains) facilitate substrate transfer, or enzyme activity, over a protein bound-
ary. Representing COM2-type boundaries on compounds highlights molecular
components corresponding to protein boundaries (Fig. 3.8). This representation
provides an opportunity to visualise natural products as molecular components
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based upon protein boundaries with COM domains. Exploitation of these COM
domains could facilitate the creation of novel hybrid-compounds, assembled in a
combinatorial fashion, based upon a framework underpinning bioactivity.
3.2 Bioactivity of natural products utilising type
2 COM domains
The list of natural products utilising COM2-junctions during their biosynthesis is
extensive, and demonstrates a range of biological activity. Bacitracins are a fam-
ily of commonly used antibiotics which interfere with cell wall and peptidoglycan
biosynthesis. The COM2-juction within bacitracin NRPS, can be mapped to an
amide linking the macrocycle to the linear peptide region. It is plausible that
COM2-junctions could be exploited to exchange the linear component of baci-
tracin with another molecular constituent found upstream of a COM2-junction
from a di↵erence biosynthetic pathway.
Romidepsin (also known as Istodax) contains a COM2 junction during its
biosynthesis, condensing valine with a polyketide. In 2009, romidepsin gained
FDA approval for the treatment of cutaneous T-cell lymphomas after receiving a
fast-track designation (Gloucester Pharmaceuticals). Later, in 2011, it was also
approved for other peripheral T-cell lymphomas. It represents a noteworthy ex-
ample of a natural product that exhibits beneficial pharmaceutical properties.
Another class of anticancer drugs are epothilones, which employ COM domains
during their biosynthesis. Epothilones prevent cancer cells from dividing by in-
terfering with tubulin. Several analogues are in clinical development for various
cancers. One epothilone analogue, ixabepilone was approved for the treatment of
advanced breast cancer in 2007 (R-PHARM). The methyl located on the thiazole
of epothilones, represents the COM2-junction in the epothilone PKS-NRPS. The
PKS, found upstream of the COM2 boundary, contains an acetyl-PCP domain,
which becomes condensed to cysteine from the downstream NRPS. By modifying
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the PKS component of the biosynthetic pathway, the COM2-junction could be
utilised to generate novel epothilone analogues, where the methyl is exchanged
for a larger polyketide, or hybrid polyketide-nonribosomal peptide molecule.
Large structural variations are represented across the collection of molecules
that utilise COM2 domains within their respective biosynthetic pathways. Some
are relatively large cyclised lipopeptides, like syringopeptin, xantholysin, to-
laasin, puwainaphycins, white line inducing principle, entolysin, massetolide and
poaeamide. Each of these compounds show: variation in length, amino acid com-
ponents, macro-cyclisation size and type, and the position of reactions mediated
by COM2 domains. Syringopeptin contains a particularly large protein (around
1.5 MDa), consisting of twelve extension modules encoded by a 40 kb gene. Such a
large protein shows that some COM2-junctions at NRPS-NRPS boundaries could
potentially be replaced by a single protein (at least in Pseudomonas syringae).
However, one advantage of using COM domains, compared with a single protein
without a boundary, is the opportunity for COM crosstalk and sampling other
potential biosynthetic pathways during evolution.
A common feature of COM2-derived compounds is a thiazole at the COM2-
junction (e.g. myxothiazol, melithiazole, pyochelin, thiazostatin, watasemycin,
coelibactin, equibactin, epothilone), or an oxazole (e.g. DKxantheme, leupyrrin).
From the untapped potential of cryptic biosynthetic gene clusters, the most fre-
quent COM2N -containing genes are also predicted to produce thiazoles or oxa-
zoles. Careful dereplication procedures will uncover the fuller extent of diversity
within cryptic gene clusters and putative structures of natural products. De-
spite the relatively high frequency of PCP and cyclisation domains at COM2
boundaries, many natural products contain thiazole and oxazoles without cross-
ing COM boundaries. These features can be observed in natural products that
utilize COM domains corresponding to positions elsewhere in a given compound
(e.g. barbamide, coelibactin, cystothiazole, tubulysin).
The most common type of enzyme found adjacent to COM2C and COM2N
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Figure 3.8: a) Enacyloxin IIa communication-mediated chain release. b) Exam-
ples of natural products biosynthesised utilising COM2 domains. Red bold lines
indicate the point of a COM2 boundary during biosynthesis, which is also reflected
in some colour changes for molecular constituents. Macrocyclisations, and other
linkages, are indicated with grey bonds at boundaries with colour changes.
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Figure 3.8 (cont.)
domains, within the atlas PKS/NRPS database, are PCP and heterocyclisation
domains respectively. Other types of enzymes found bordering COM2-junctions
are shown in Fig. 3.9a. PCP domains can utilise COM2 domains to pass a sub-
strate to condensation domains (like in enacyloxin PKS-NRPS), and epimerising
condensation domains. Thioester-reductase domains are identified downstream
of some COM2N domains, either as an isolated entity, or with an additional do-
main of unknown function (predicted to have a beta-lactamase-like fold). The
COM2N domain is situated in the centre of the protein in this case. PKS-NRPS
hybrids can be formed over COM2 boundaries, with ACP domains passing in-
termediates to condensation, or heterocyclisation, domains. These observations
suggest a degree of promiscuity between ACP and condensation, or cyclisation,
domains which could be exploited to engineer novel PKS-NRPS hybrid biosyn-
thetic pathways.
Whilst the COM2C motif is most frequently preceded by a carrier protein, it
can also be found after oxidising enzymes (e.g. melithiazol and myxothiazol PKS-
NRPSs). In these examples the modular setup is Cy-A-PCP-Ox-COM2C followed
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by COM2N -Cy-A-Ox-PCP, where each oxidase acts on the cysteine-derived dihy-
drothiazoles within each module. The PCP-bound intermediate needs to locate
the downstream cyclisation domain over the COM2-junction despite the addi-
tional oxidase within the PCP-Ox-COM2C module. This system raises some
questions on the quaternary structure of these multi-enzyme complexes, and the
relative positions of each enzyme around COM2-junctions.
Whilst the atlas PKS/NRPS database was used to identified many COM2N
domains, the larger non-redundant protein database was used to explore varia-
tion in the domains acting across COM2 boundaries. Using HMM searches, more
exotic systems were identified that deviated from those found within the atlas
PKS/NRPS database (Fig. 3.9b). In one example, a thioesterase (type I) was
identified to putatively facilitate chain release over a COM2-junction from an
upstream carrier protein (Appendix Fig. 7.14). This is similar to the thioester-
reductase example, and could potentially be exploited for the targeted release
of carrier protein-bound intermediates, or similar bioengineering applications ex-
ploiting COM2 boundaries.
Ox
ACP
PCP
Clcl
Cd
Cy
TR
bL
TR
MT
H
A
TE
?
PCP
ACP
Cy
?
a b
Figure 3.9: Examples of domains found adjacent to COM2N domains. a) Do-
main pairs identified from atlas PKS/NRPS database, Clcl - d-amino acid conden-
sation domain, Cy - heterocyclisation domain, Cd - dual epimerising and condens-
ing domain, TR - thioester-reductase, bL - beta-lactamase-like, Ox - oxidase. b)
domain pairs from searching the non-redundant protein database, H - halogenase,
question marks denote domains of unknown function.
Two examples were found involving enzymes of unknown function based on
homology to characterised enzymes (Appendix Fig. 7.9, 7.10). These proteins oc-
cur upstream of an adenylation domain, and downstream of a cyclisation domain
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or ACP. One cryptic biosynthetic pathway was identified with a trans-acting
COM2N -cMT protein (Appendix Fig. 7.12). This hybrid PKS-NRPS has two
COM2C domains and three COM2N domains. Assuming biosynthetic colinearity,
the COM2N -cMT protein shares a COM2C domain with a condensation domain.
It putatively acts to C-methylate a PCP-bound threonine residue, before con-
densation with N-methylated proline. Though this is an isolated cryptic example
pathway, it represents the diversity of biochemistry facilitated by COM2 domains.
There are two families of chlorinated compounds which contain COM2 do-
mains within their biosynthetic pathways, aeruginosins and cyanopeptolins. Each
NRPS contains one COM2C domain and two COM2N domains, where one of the
COM2N domains is located N-terminal to the halogenase enzyme (Fig. 3.10).
Assuming colinearity, the halogenase is proposed to utilise the COM2N domain
to chlorinate the phenyl PCP-bound intermediate from the downstream NRPS.
Then, the upstream NRPS condenses the chlorinated intermediate, with the PCP-
bound amino acid, from the downstream NRPS module. This would suggest some
level of promiscuity of the COM2C domain towards each COM2N domain. To ob-
tain a high proportion of chlorinated product the halogenase must perform its
catalytic activity preferentially over the downstream condensation domain. Such
information may be encoded in each COM2N domain, in terms of binding a nity
with COM2C . The identification of the COM2N -halogenase protein reveals a bio-
physical basis for chlorination activity acting on the PCP-bound intermediate,
compared to the NRPS product after chain release.
3.2.1 COM2N domain located away from a terminus
The hybrid PKS-NRPS, involved in the biosynthesis of the neurotoxin jamaicamide,134
features two COM2N domains (Fig. 3.11). A COM2C motif can be found at the
C-terminus of JamN, which is proposed to form an intermolecular interaction
with the COM2N domain identified in JamO. Another COM2N is found in JamL,
between the ACP and C domains, at the PKS-NRPS interface. An additional
46
S
O
OH
A KR CP
H
S
C A CP
O
NH
O
OH
OH
OH
E
(Cl)
(Cl)
aerA
aerJ
aerB
Microcystis aeruginosa
aeruginosin
... ...
Figure 3.10: COM2-boundary within aeruginosin NRPS showing a trans-acting
COM2N -halogenase.
COM2C domain was not identified at the C-terminus of any protein within the
jamaicamide biosynthetic gene cluster, and was also not identified directly up-
stream of the COM2N domain in JamL. It is unclear whether the COM2N domain
within JamL performs an intermolecular interaction, or is a consequence of genetic
recombination. The previously unidentified oxidase in JamL may utilise an in-
teraction between COM2N from JamL and the COM2C from JamN to oxidise the
ACP-bound intermediate on JamN. However, these stages of jamaicamide biosyn-
thesis are poorly understood due to di↵erences between the predicted molecular
structure arising from this unusual domain architecture and the structure of ja-
maicamides.
3.3 Crosstalk at COM2 junctions
The identification of putative COM2N domains, from many biosynthetic path-
ways, provides an opportunity to exploit these intermolecular interactions to de-
sign novel products. Some COM2 junctions may have a degree of inherent promis-
cuity, as shown in examples where two COM2N domains share a single COM2C
domain. Whilst other examples, such as those with two COM2-junctions, must
prevent crosstalk, where a single biosynthetic route is followed.
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Figure 3.11: Biosynthesis of jamaicamide, showing COM domains. Interme-
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3.3.1 Watasemycin NRPS
Two proteins within the watasemycin NRPS, Sven 5912 and Sven 5917, are pro-
posed to contain a COM2-junction. A COM2N domain was identified within
Sven 0517 from watasemycin NRPS, and subsequently a putative COM2C do-
main was proposed in Sven 0512 (Fig. 3.12a). These NRPSs were used as a
model system, to investigate the promiscuity of COM2-junctions. By creat-
ing a hybrid COM2-junction using the COM2C domain from Sven 0512 NRPS,
and the COM2N domain from Bamb 5915 (of enacyloxin biosynthesis), a hybrid
watasemycin-enacyloxin compound could be biosynthesised, assuming some sub-
strate tolerance of downstream enzymes. This compound would consist of the
intermediate bound to the C-terminal PCP of Sven 0512, condensed with the
substrate of the enacyloxin condensing enzyme, (10R,30R,40S)-DHCCA, at the
30-OH position (Fig. 3.12b).
The work towards the creation of a watasemycin-enacyloxin compound, in-
cluded chemical synthesis of precursors, and in vitro assays, which were performed
in collaboration with Matthew Beech (chemical synthesis of watasemycin interme-
diate), Shanshan Zhou (cloning PCP-COM2C from Sven 0512), Christian Hobson
(coupling watasemycin intermediate to protected pantetheine) and Dr Matthew
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Figure 3.12: a) Watasemycin NRPS. b) Hypothetical watasemycin-enacyloxin
hybrid compound.
Jenner (provided CoA biosynthetic enzymes and performed PCP loading as-
say). The free-acid of the PCP-bound intermediate, (R)-2-(2-hydroxyphenyl)-
4,5-dihydrothiazole-4-carboxylic acid, was chemically synthesised and coupled to
protected pantetheine, before deprotection. A set of three enzymes were used to
form a CoA derivative from the pantetheine-coupled compound, a pantothenate
kinase (PanK), a phosphopantetheine adenyltransferase (PPAT) and a dephos-
phocoenzyme A kinase (DPCK).135 Forming the CoA derivative, provides a closer
mimic of the substrate of phosphopantetheinyl-transferases (e.g. Sfp from sur-
factin NRPS). Loading a CoA derivative onto an apo-carrier protein can usually
be accomplished using the relatively promiscuous Sfp enzyme with Mg2+ as a co-
factor. Unfortunately, the CoA derivative of the PCP-bound intermediate could
not be transfered onto the C-terminal PCP-COM2C from Sven 0512 using Sfp.
The relatively hindered ↵-position at the sterocenter of the thiazole is one possible
explanation for the observed temperance of Sfp for this particular substrate.
3.3.2 Cross-talk assay
To investigate the promiscuity of COM2 domain interactions, a condensation as-
say was designed using the PCP-COM2C domain from watasemycin NRPS and
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the COM2N -C domain from enacyloxin biosynthesis. The assay is based on the
transfer of an acetate unit across the hybrid communication boundary for con-
densation with shikimate, as the more complex watasemycin intermediate could
not be loaded onto PCP-COM2C using Sfp. Acetyl-PCP-COM2C was observed
to condense with shikimate via the COM2N -C domains (Fig. 3.13a), exhibiting a
similar profile E.I.C. as for the PCP-COM2C from enacyloxin (Fig. 3.13b). The
COM2C domains share a common EYEEG subsequence from the terminal nine
amino acids (SEYEEGVIR from enacyloxin PKS-NRPS and LVEYEEGEL from
watasemycin NRPS), which may contribute to the inherent compatibility of this
hybrid COM2-junction.
a
b
Figure 3.13: a) Crosstalk scheme with watasemycin and enacyloxin domains.
b) E.I.C for acetylated shikimate from crosstalk assay.
3.3.3 Other carrier protein-condensation domain bound-
aries
The COM2N HMM has revealed many instances of COM2-junctions at PCP-to-
condensation domain protein boundaries. However, some PCP and condensation
domain boundaries do not utilise COM2 domains. The VpsA-VpsB boundary
within vancomycin NRPS, and homologous NRPSs, possess COM1 domains at
PCP and condensation domain boundaries. In these examples the PCP domain
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possesses an adjacent COM1C domain, even though COM1C domains are most
commonly associated with an epimerisation domain at a boundary with a conden-
sation domain. The relatively short length of COM1N domains (around 17 amino
acids), means that the COM1N domain locates to the N-terminal subdomain of
the condensing enzyme. If the binding partner is an epimerase-COM1C protein,
then this domain must also situate to the similar vicinity due to the short length
of COM1C . This must also hold true when the binding partner is PCP-COM1C .
In VpsA-VpsB within vancomycin NRPS, there appears to be a small linker of
approximately 11 amino acids between the PCP and the COM1C domain. This
may help facilitate the location of the PCP to the entrance face of the down-
stream condensation domain, and the exit face of the upstream condensation
domain. For comparison, COM2N domains are located at the C-terminal subdo-
main of condensing enzymes, at boundaries between PCP-COM2C and COM2N -C
domains (Fig. 3.14), where a 17 amino acid linker extends from the condensation
domain to the COM2N domain.
C C
a b
Figure 3.14: a) COM2N -C structure from enacyloxin PKS-NRPS (Bamb 5915)
b) COM1N -C structure from surfactin NRPS.24
As well as COM1N and COM2N domains, PKS-like docking domains asso-
ciated with ACP and KS protein boundaries can also be identified preceding
condensation domains. In the bacillaene biosynthetic machinery, a PKS-NRPS
boundary lies in between an ACP and a condensation domain. The condensation
domain is proceeded by a region which was identified as a type 3 docking domain
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using a pHMM. To date, this class of docking domain has only been reported be-
fore KS domains. This is the first instance of a PKS-like docking domain found
preceding an NRPS condensation domain. This type of docking domain is rel-
atively short and has a helical structure. It is expected that the higher-order
architecture of this ACP-dd3C and dd3N -C complex would resemble the com-
plex of PCP-COM1C and COM1N -C, despite a di↵erent type of intermolecular
interaction.
3.4 Conclusion and further work
The development of HMMs to describe docking domains and COM domains have
demonstrated the ubiquity of these appendages within modular PKSs and NRPSs.
However, improved methods for their identification and classification, remains a
challenge due to their small size. The dd2-class of docking domains have been
identified within 22 biosynthetic pathways, in addition to those previously re-
ported. This further demonstrates the widespread use of docking domains, and
opportunities for exploiting this class of interaction sites. HMMs have uncovered
instances of docking domains that are not located at protein termini. Experi-
mental investigation of these internal docking domains may elucidate functional
recruitment of trans-acting enzymes, or they may exist as a consequence of evo-
lutionary development.
Inspection of terminal amino acid sequences from PKS and NRPS proteins
provided motifs corresponding to docking domains, and components of domains
that accommodate the terminal amino acid sequence. Amongst type II PKS
domains and loading domains, four classes of docking domains were independently
identified within PKSs, during searches for terminal motifs. Resulting HMMs
facilitated the identification of each of these classes from databases of PKS and
NRPS proteins. Extension of this method, to larger PKS and NRPS protein
databases, and investigations of less frequent motifs, should elucidate novel forms
of docking domains, and facilitate their annotation within modular PKSs and
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NRPSs.
A novel form of intermolecular interaction has been proposed at boundaries
between C-terminal trans-AT KS domains and N-terminal DH domains, which
diverges from the paradigm of two terminal docking domains. A C-terminal
peptide is proposed to interact directly with the N-terminal DH domain. In each
example of this domain architecture, the KS domain does not contain a trans-AT
docking domain, or an associated motif that binds to a KS domain before forming
the following modular components. The consistent failure to identify this motif
may suggest a breakdown in the quaternary structure of adjacent modules, as
it appears to direct the downstream module away from the upstream module.
This is one possible explanation for additional KR activity, where KR domains
are only located in adjacent modules. Biophysical and biochemical experiments
should provide additional insight into these features.
The classification of N-terminal DH domains, involved in this putative form
of intermolecular interaction, serendipitously described DH domains that were
not located at the N-terminus. However, each of these DH domains correlated
with a (2E,4Z)-configured diene, situated at the ACP-bound intermediate within
the same module. The identification of these DH domains, within archetypal
cis-AT PKS domain organisations, suggests that this class of DH domain acts
sequentially to dehydrate two hydroxyls, in a stereospecific manner. An HMM
that describes this domain has predicted many (2E,4Z)-configured dienes within
characterised PKS products, but its value in predicting these features within
cryptic PKSs, is yet to demonstrate its full potential. The proposed function
and mechanism of this class of DH domain would benefit from in vitro assays of
substrate mimics to probe their native function.
The identification of a COM2N domain in the enacyloxin PKS-NRPS led to
the development of an HMM that described intermolecular interactions within a
range of biosynthetic pathways. These results show a clear region of conservation
on the corresponding C-terminal binding partner, but methods for its indepen-
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dent identification remains a considerable challenge. The identification of type 2
COM boundaries may provide assistance to establish biosynthetic order within
biosynthetic pathways, when the colinearity rule is not adhered to. The num-
ber of characterised natural products, biosynthesised using type 2 COM domains
is extensive, demonstrating a range of beneficial activities from a diverse set of
producing organisms. The number of cryptic biosynthetic gene clusters encoding
COM domains represents even more diversity, in terms of catalysis across protein-
protein boundaries. There are trans-acting thioesterases, thioester-reductases,
halogenase, methyltransferases and enzymes of unknown function, to name a few.
This discovery provides many opportunities for exploiting these attributes, and
ventures to engineer novel biosynthetic pathways. The identification of NRPSs
containing multiple type 2 COM boundaries, suggests a measure of selectivity
is required to avoid native crosstalk. However, the exact nature of this selec-
tivity remains an opportunity for experimental investigation, within biosynthetic
pathways containing multiple COM domains.
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Chapter 4
Genomics-driven discovery of an
enacyloxin analogue, vibroxin
4.1 Genomics-driven drug discovery
The number of microorganisms with sequenced genomes has escalated, as DNA
sequencing technology has become faster and inexpensive. Databases of genomes
can be mined, by searching for biosynthetic gene clusters using a set of compu-
tational programs,136 to evaluate their biosynthetic potential. Within any given
gene cluster, genetic components can be assigned putative functions based upon
homology to genes of known function. In the case of large modular PKS and
NRPS genes, their corresponding amino acid sequences can be partitioned into
catalytic domains. Analysis of these domains can be used to predict the specificity
of enzymes, and thus infer putative core molecular structures of corresponding
natural products.
4.2 Rhizosphere-associated Vibrio
Many Gram-negative bacteria from theVibrio genus are renowned human pathogens,
causing cholera137 and food-borne infections138 globally. Outbreaks of Vibrio-
related food poisoning frequently occur in tropical coastal areas, and often orig-
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inate from undercooked or raw shellfish,139 as many Vibrio species live sym-
biotically within the organs of marine invertebrates140 and fish.141 Whilst the
pathogenic properties of marine Vibrio sp. are relatively well-studied, it is emerg-
ing that some Vibrio sp. diverge from this paradigm, occupying alternative eco-
logical niches, such as the plant rhizosphere within salt marshes.142–144
In 2007, a red-pigmented strain, Vibrio rhizosphaerae MSSRF3T, was isolated
from the rhizosphere region of mangrove-associated wild rice (Porteresia coarc-
tata Tateoka) within the Pichavaram forest (India). It was the first Vibrio strain
to show growth-promoting activity towards plants, as well as antibacterial ac-
tivity against the phytopathogens Xanthomonas oryzae, Erwinia carotovora and
Pseudomonas syringae.145 This activity was observed in cell-free culture fractions,
indicating that V. rhizosphaerae produces an extracellular bioactive compound.
However, no such compound has so far been identified, and the underlying mech-
anism causing this beneficial bioactivity remains elusive.
4.3 Natural products from Vibrio
Marine Vibrio sp. produce an extensive collection of bioactive natural products146
(Fig. 4.1), including anticancer, antibacterial, quorum sensing interference com-
pounds and sodium channel inhibitors. To date, most natural products isolated
from Vibrio sp. are derived from non-ribosomal peptides, or are N-containing
molecules that are biosynthesised by NRPS-independent methods. Some well-
known examples of compounds produced by Vibrio strains with potential as
promising drug leads include prodigiosin, kahalalide F, and tetrodotoxin.
The red-pigmented antibiotic prodigiosin from V. gazogenes,147 V. ruber 148
and V. psychroerythreus,149 along with its cyclised prodigiosin analogue,150,151
has demonstrated benefits for anticancer therapy.152 Its drug variant, obatoclax,
reached phase II clinical trials153 for the treatment of leukemia, lymphoma, mas-
tocytosis and myelofibrosis, but exhibits a low therapeutic window due to toxic
e↵ects.154
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Figure 4.1: Examples of bioactive compounds isolated from Vibrio sp.
Kahalalides, isolated from V. mediterranei,155 display an attractive spectrum
of activity against cancer cell lines and AIDS-related opportunistic infections.156
The compound kahalalide F reached phase II clinical trials for liver carcinoma,
prostate and lung cancer,156 and for treatment of patients su↵ering from severe
cases of psoriasis (PharmaMar).
Perhaps the most infamous natural product from Vibrio is tetrodotoxin.157,158
Some Vibrio sp. live symbiotically within pu↵erfish and produce the potent neu-
rotoxin tetrodotoxin, making the pu↵erfish one of the most poisonous vertebrates
in the world. Tetrodotoxin, extracted directly from pu↵erfish, is currently in
phase II and phase III clinical trials for pain relief during chemotherapy treat-
ments.159
Whilst marine Vibrio sp. have been shown to produce a range of bioac-
tive compounds, rhizosphere-associated Vibrio sp. remains an underexploited
source of antimicrobial metabolites. In an e↵ort to discover novel bioactive com-
pounds, the genome of V. rhizosphaerae was analysed for the presence of spe-
cialised metabolite biosynthetic gene clusters.
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4.3.1 Genome-mining of V. rhizosphaerae
Forty seven sca↵olds from the genome assembly of V. rhizosphaerae MSSRF3T
were processed using antiSMASH42 to identify specialised metabolite biosynthetic
gene clusters. A total of twelve clusters were identified: nine NRPSs, one ectoine
pathway, one bacteriocin pathway and one trans-AT PKS. This number of biosyn-
thetic gene clusters demonstrates the untapped potential for bioactive metabolite
production within this strain.
Some of the NRPS clusters were incomplete, located at sca↵old boundaries.
While other NRPS clusters were very small, containing only one or two adenyla-
tion domains. The largest complete NRPS gene cluster was situated 4 kb from
a trans-AT PKS cluster on sca↵old KL543967. It consists of three large multi-
modular genes encoding six adenylation domains with predicted specificities for
asp-gly-ser-ser-?-gly (Fig. 4.2). Genes encoding a putative dioxygenase and pep-
tidase were located peripherally. However, the product of this biosynthetic gene
cluster remains unknown.
C A CP
ser
C A CP
gly
CP CP E C A CP
C A CP E C A CP CP E C A CP TE
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ctg1_243
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ctg1_241
Figure 4.2: NRPS from sca↵old KL543967 of V. rhizosphaerae.
The trans-AT PKS gene cluster (Fig. 4.7) from sca↵old KL543967 of V. rhi-
zosphaerae MSSRF3T was found to have significant homology to the enacyloxin
biosynthetic gene clusters from B. ambifaria80 and B. gladioli160 (Appendix Ta-
ble 7.2). Thus, a search was conducted to uncover an enacyloxin-like natural
product from V. rhizosphaerae, named vibroxin.
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4.4 Vibroxin structure elucidation
The production of vibroxin by V. rhizosphaerae was not observed from cultures
grown in liquid media (TSB2S and BSM2S), and only small amounts could be
detected in ethyl acetate extracts from cultures grown on solid media. Enhanced
production of vibroxin compounds was observed using glycerol as a carbon source
instead of glucose (Fig. 4.3). Thus, BSM2S-glycerol solid medium was chosen
for larger-scale (1 L) production of vibroxin. Vibroxin was purified from the
ethyl acetate extracts of the agar by semi-preparative HPLC to give 0.3 mg
purified vibroxin as a yellow/brown solid for structural characterisation by NMR
spectroscopy and mass spectrometry.
Figure 4.3: LC-MS analysis of ethyl acetate extracts from V. rhizosphaerae
cultures, measuring absorbance intensity at 360 nm. Extracts were derived from
cultures grown on equal amounts of BSM2S-agar with; a) glucose as a carbon
source, b) glycerol as a carbon source.
The crude ethyl acetate extract of V. rhizosphaerae grown on BSM-agar con-
tained a prominent red-pigmented compound, similarly to the culture itself. LC-
HR/MS analysis of the extract showed the production of an analyte with an
absorption maximum at 555 nm, and a molecular formula C20H25N3O (calcu-
lated for C20H26N3O+: 324.2070, found: 324.2092). This molecular formula is
identical to that of the red pigmented prodigiosin.
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Aside from the red-pigmented compound, LC-HR/MS analysis of the crude
extract revealed the presence of one major and one minor metabolite with an ab-
sorption maximum around 360 nm (Fig. 4.3), indicative of the predicted pentaene
subunit vibroxin (similarly to enacyloxin).
4.4.1 LC-HR/MS
The molecular formula of vibroxin was shown to be C33H47ClO9 (m/z calculated
for C33H47ClNaO
+
9 : 645.2806, found: 645.2803) (Fig. 4.4). Additionally, in-source
fragmentation of the [M+H]+ ion yielded a daughter ion with m/z 605.2881, cor-
responding to dehydration of the parent ion. The high-resolution mass spectrum
observed for vibroxin is consistent with the predicted isotopic distribution for a
C33H47ClNaO
+
9 species (Fig. 4.4).
Figure 4.4: a) MS isotopic pattern for ion 645.2803 from the retention interval
16.0-16.2 minutes, b) predicted mass spectrum for C33H47ClNaO9+.
4.4.2 NMR spectroscopic analysis
The structure of vibroxin was solved using 1H-1H COSY, 1H-13C HMBC, 1H-
13C HSQC and 1H-1H NOESY correlation spectra (Fig. 4.5). The 1H and 13C
assignments are listed in Table. 4.1. Quaternary carbon chemical shifts were
calculated from HMBC resonances. A characteristic doublet at 1.02 ppm suggests
the presence of an iso-propanyl group at the terminus distal to the cyclohexane
moiety.
A 3JH,H coupling constant of 15.1 Hz for H-18 and H-19 is consistent with
an E-configured double bond between positions C-18 and C-19. Position C-15
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exhibits couplings to C-14 and C-16, and has a chemical shift consistent with a
hydroxyl group at this position. The minor vibroxin species, coined iso-vibroxin,
demonstrated visible light-inducible isomerisation from vibroxin during purifica-
tion. This species corresponds to the retention interval 16.5-16.6 minutes. As a
consequence, light exposure was minimised during all procedures after purifica-
tion of vibroxin.
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Figure 4.5: The structure of vibroxin showing correlations from NMR exper-
iments: 1H-1H COSY (bold), 1H-13C HMBC (arrows), 1H-1H NOESY (dashed
arrows).
4.4.3 Base hydrolysis of vibroxin
The cyclohexane moiety at the terminus of vibroxin contains three stereocenters.
Purified vibroxin was treated with a potassium hydroxide to hydrolyse the ester
at the junction between the polyketide and the dihydroxy-cyclohexane carboxylic
acid (DHCCA) to investigate the stereochemistry of this derivative (Fig. 4.6a).
LC-HR/MS analysis was performed on hydrolysed vibroxin, hydrolysed enacy-
loxin, and authentic standards (10S,30R,40S)-DHCCA and (10R,30R,40S)-DHCCA.
The DHCCA products were identified from extracted ion chromatograms using
m/z=183.0628, which corresponds to the sodiated adduct (Fig. 4.6b). The re-
tention time of the DHCCAs from hydrolysed vibroxin, hydrolysed enacyloxin
and the (10S,30R,40S)-DHCCA standard are consistent with each other, whilst
the (10R,30R,40S)-DHCCA standard possesses a later retention time (the small
impurity with a retention time of 7.2 minutes arises from another DHCA di-
astereometer). This result provides support that the relative stereochemistry of
the cyclohexane moiety in vibroxin is the same as in enacyloxin, although the
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Table 4.1: NMR assignment for vibroxin (MeOD, 500 MHz, 298 K).
Position
 H/ppm
(no. of protons, multiplicity, J/Hz)
 C/ppm
10-COOH 178.1
10 2.52 (1H, m) 38.5
20
2.17 (1H, m)
31.5
1.74 (1H, m)
30 5.22 (1H, m) 72.2
40 3.73 (1H, m) 69.6
50 1.82 (2H, m) 28.3
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2.05 (1H, m)
26.8
1.57 (1H, m)
1 167.4
2 6.03 (1H, d, 15.0) 120.2
3 7.45 (1H, dd, 15.0, 11.0) 145.1
4 6.55 (1H, dd, 15.0, 11.0) 125.9
5 6.78 (1H, br d 15.0) 145.3
6 135.8
6-Me 1.97 (3H, br s) 11.2
7 6.44 (1H, br d, 10.0) 135.6
8 6.77 (1H, m) 130.1
9 6.77 (1H, m) 130.1
10 6.44 (1H, br d, 9.5) 126.4
11 140.7
12 2.88 (1H, dq, 9.5, 7.0) 46.0
12-Me 1.13 (3H, d, 7.0) 14.8
13 3.96 (1H, br, d, 9.5) 70.8
14 3.37 (1H, m) 72.8
15 3.94 (1H, m) 68.2
16
2.05 (1H, dd, 17.0, 4.5)
41.1
1.57 (1H, m)
17 4.41 (1H, m) 68.8
18 5.67 (1H, dd, 15.0, 6.5) 134.2
19 6.21 (1H, dd, 15.0, 10.0) 129.7
20 6.03 (1H, dd, 15.0, 10.0) 126.9
21 5.65 (1H, dd, 15.0, 6.5) 141.1
22 2.33 (1H, sept, 7.0, 6.5) 31.3
23 1.02 (6H, d, 7.0) 21.4
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absolute configuration has not been elucidated to date.
Figure 4.6: a) Base hydrolysis reaction for vibroxin and enacyloxin, showing the
sterochemistry of DHCCA standards. b) Extracted ion chromatograms from LC-
HR/MS analysis for DHCCA using m/z=183.0628 corresponding to the sodiated
adduct. i) hydrolysed vibroxin, ii) hydrolysed enacyloxin IIa, iii) (10S,30R,40S)-
DHCCA, iv) (10R,30R,40S)-DHCCA.
4.5 Vibroxin gene cluster
4.5.1 Gene annotations
The vibroxin biosynthetic gene cluster contains seven large PKS genes (vbxD-
vbxJ ) encoding modular components of polyketide synthesis, of which vbxJ is
a hybrid cis-AT and trans-AT PKS gene based on phylogenetic analysis. The
domains proximal to the C-terminus of VbxJ constitute the trans-AT-like region,
where a non-elongating KS domain is present (KS0). This domain shall hereby be
referred to as an ACP trans-acylase enzyme (TA) which more accurately describes
its function. A hybrid PKS-NRPS gene was identified by domain components
encoded by vbxQ. A type II thioesterase is encoded by vbxC.
An NRPS-like condensation domain was identified in VbxO, where a COM2N
domain is located at the N-terminus. A putative COM2C motif is proposed to
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be present at the C-terminus of VbxQ within the sequence DEYEEGFIV (cf.
SEYEEGVIR in the homologous Bamb 5917). Genes vbxP, vbxN, vbxM, vbxL
and vbxK are proposed to encode enzymes involved in 30,40-dihydroxycyclohexane
carboxylic acid (DHCCA) biosynthesis by homology to genes from the enacyloxin
biosynthetic gene cluster. Tailoring enzymes include a putative non-heme iron
dependent oxygenase, vbxB, and a putative FADH2-dependent chlorinase, vbxA.
There are two regulatory genes, vbxR and vbxS. At the cluster boundary, vbxT is
predicted to encode a TIM-barrel e✏ux pump.
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Figure 4.7: Vibroxin biosynthetic gene cluster.
4.5.2 Comparison with enacyloxin biosynthetic gene
cluster
In the enacyloxin biosynthetic gene cluster, there are three genes that encode tai-
loring enzymes (bamb 5930 -bamb 5932 ), and a LuxR-like regulation gene (bamb 5910 ),
which are not present within the vibroxin biosynthetic gene cluster (Fig. 4.8). All
of these genes are located at the periphery of the enacyloxin biosynthetic gene
cluster. Furthermore, regulatory gene vbxR is located at the opposite end of the
gene cluster relative to the location of the homologous gene bamb 5911 within
the enacyloxin biosynthetic gene cluster. The genes vbxL-vbxQ (homologous to
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bamb 5917 -bamb 5912 ), appear to have undergone an inversion event (or multi-
ple equivalent processes), whereby bamb 5917 has become truncated compared
with vbxQ (Fig. 4.8). Rigorous inspection of the domains encoded by gene vbxQ
reveals four structural components: a region with a relatively low homology to
the C-terminal part of a KS domain (presumed inactive), a KS-to-AT linker do-
main (or a so-called trans-AT docking domain), a PCP domain, and a COM2C
motif. The KS-like region is absent in Bamb 5917.
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Figure 4.8: Comparison of the vibroxin biosynthetic gene cluster (vbx ) and the
enacyloxin biosynthetic gene cluster (bamb). Asterisks denote genes that have no
corresponding homologous gene within the vibroxin biosynthetic gene cluster.
The PKS gene that is most di↵erent to its enacyloxin gene homologue is
vbxI, appearing 31% longer in sequence than bamb 5920. This is, in part, due
to the presence of an additional KR and ACP domain. Despite the absence of
this KR domain in Bamb 5920, a reduction at the  -position of the ACP-bound
thioester intermediate is still predicted to occur at this stage during enacyloxin
biosynthesis. Within VbxI, an additional KS-AT linker domain exists, as well as
a region with low homology to an AT domain (not identified using AT HMMs)
between the N-terminal KS and the subsequent DH domain (Fig. 4.9). This linker,
and the low homology AT region, appear to have been excised in Bamb 5920, as
the KS and DH appear concatenated. Typically, malonylation of a functional
ACP domain is associated with the presence of either, an AT domain within the
same module, or a trans-AT docking domain. Within Bamb 5920, neither of these
features can be identified within the N-terminal module, and there is no space for
any unidentified domains downstream of the KS or upstream of the DH domain.
Yet, given the structure of enacyloxin, this KS is presumed to possess elongation
activity. Whilst AT-like fragments are found in VbxE, VbxI and VbxJ, they are
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assumed to arise from evolutionary excision, and predicted to be catalytically
inactive. Presumably, the AT activity of domains in these modules was replaced
by another AT at some evolutionary time point, leaving little selective pressure
to maintain cis-acting ATs at such positions.
The vibroxin and enacyloxin biosynthetic assembly lines consist of both trans-
AT and cis-AT PKS components (Fig. 4.9). The di↵erences between these types
of PKS components can be determined by phylogeny of KS and AT domains.
Trans-AT PKSs typically employ an AT domain acting in trans, and cis-AT
PKSs use a downstream AT domain within the same multi-enzymatic protein,
but this does not always hold true.161 Three motifs can be identified downstream
of a trans-AT KS: two motifs corresponding to a KS-AT linker denoted KAn
and KAc, and a C-terminal KS motif denoted KSc (n.b. shorter motifs are more
challenging to identify with HMMs and therefore often give false negative results,
e↵ectively failing to identify them). Together these three motifs form a trans-AT
docking domain (although the exact function of this domain is inconclusive) with
a region of low conservation between the KS-AT linker motifs. This region of low
sequence conservation has also been proposed to interact with other trans-AT
docking domains.162 Structural representations of the di↵erences between trans-
AT and cis-AT PKS domains are shown in Fig. 4.9. The only (phylogenetic)
trans-AT part of each biosynthetic cluster is the C-terminal region of VbxJ and
Bamb 5919. All other KS domains belong to the cis-AT clade, even those without
adjacent AT domains. Downstream of some of these KS domains, AT fragments
can be identified using AT HMMs (labelled with asterisks in Fig. 4.9). These AT
fragments are presumed to be non-functional in terms of malonylation because
they lack the catalytic amino acid residues within conserved motifs. Instead, these
AT-homologous fragments may result from partial AT excision, as a transition
towards the domain architecture exhibited in trans-AT PKSs, despite a di↵erent
phylogenetic origin based on the definition employed using KS clades. Whilst
some AT fragments are found in vibroxin PKS genes and not within enacyloxin
66
PKS genes, there is often unannotated space to accommodate fragments. These
regions may have decreased AT-homology, preventing their identification as AT
fragments using HMMs, further supporting the proposal of evolutionary AT loss.
4.5.3 Proposed biosynthesis of vibroxin
A proposed model for vibroxin biosynthesis is outlined in Fig. 4.10. The loading
module within VbxD consists of an ‘acyl-recruitment domain’,163 an MT domain
and a GNAT domain, followed by an ACP domain. Acyl-recruitment domains
are typically found directly upstream of carbon-MT domains within PKS and
NRPS enzymes (i.e. cis-acting carbon-MTs). MT domains act on malonyl-CP,
amino-acid-CP or other biosynthetic extender units. The acyl-recruitment do-
main is considered a prefix to the MT domain and is referred to as dMT due
to its dimerisation property observed in these types of structures.164 The GNAT
domain is predicted to load the ACP domain, within the loading module, with
malonate. This event is presumably followed by di-methylation of malonyl-ACP
by the MT, and subsequent decarboxylation. Another possibility is that the
di-methylation occurs after decarboxylation, using acetyl-ACP as the substrate.
Interestingly, although the loading module in the enacyloxin biosynthetic assem-
bly line is similar in domain architecture, only a single methylation occurs.
MT and GNAT domains within loading modules have also been described
in the biosynthetic assembly lines of saxitoxin,165 gephyronic acid166 and apra-
toxin,167 which methylate once, twice, and three times, respectively. The loading
module from apratoxin contains two distinct MT domains which perform three
methylations. This example demonstrates that decarboxylation occurs, at least,
before the third methylation takes place. Given this information, and the ob-
servation that the active site for malonylation and decarboxylation are proximal
within a GNAT, it appears most credible that decarboxylation occurs before
methylation within loading modules.
Two cis-AT domains are found within the vibroxin gene cluster in VbxD and
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VbxH. These are predicted to possess substrate specificity for malonyl-CoA based
on NRPS/PKS substrate predictor14 and Minowa168 analysis. Each PKS module
within the vibroxin biosynthetic pathway is predicted to require malonyl-CoA for
chain extension but there are no other AT domains found within the gene cluster.
Therefore, either the AT domain from VbxD, VbxH, or an AT from outside of
the cluster (or any combination thereof) is predicted to load malonate onto the
ACP domains within modules where cis-AT domains are not observed.
The stereospecificity of the KR domains was predicted based upon ‘fingerprint’
rules16 regarding properties of five amino acids within a particular loop and motif
near the catalytic active site (Table 4.2). There are six DH domains within the
biosynthetic gene cluster but seven dehydrations are predicted to occur. The
DH-less modules within VbxE and VbxH could potentially utilise DH domains
from the adjacent modules. Alternatively, modules containing DH domains could
act iteratively, while DH-less modules may be skipped. However, the possibility
of module skipping is not consistent with stereochemical predictions. The DH
domain within VbxG is predicted not to dehydrate the S-configured  -hydroxyl
of the enzyme-bound intermediate within this module (similar to Bamb 5922).
The C-terminal trans-acylase (TA) domain from VbxJ contains the conserved
cysteine residue for trans-acylase activity but lacks the histidine residue required
for chain elongation, forming an AANGA sequence instead of the typical HGTGT
active motif. The KS-like fragment from VbxQ is predicted to be catalytically
inactive, since it lacks both motifs for activity. Each carrier protein possesses the
conserved serine and is therefore presumed to be catalytically active, including
the tandem ACP domains in VbxI.
Chain release is accomplished by a NRPS-like C domain with a COM2N do-
main, VbxO, and involves intermolecular condensation to a shikimate-derived
product. The proposed biosynthetic pathway for the shikimate-derived substrate
involves VbxL, VbxM, VbxN and VbxP, but it remains unclear which of these
enzymes act before or after the condensation reaction. Two tailoring enzymes are
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Table 4.2: KR stereochemistry prediction using diagnostic amino acids that were
identified from sequence alignments with KR domains of known stereospecificity.
gene
fingerprint regions KR
assignment
predicted
stereochemistry1 2 3 4 5 6
VbxD KR1 VED L Q Y T N B1 R
VbxE KR1 LAD V Q Y S N B1 R
VbxF KR1 SQQ W L Y M N A1 S
VbxF KR2 LEQ L Q Y F N B1 R
VbxG KR1 GGD W K Y F N A2 (2S, 3S)
VbxH KR1 LSD L Q Y S N B1 R
VbxH KR2 LSD L Q Y A N B1 R
VbxI KR1 LDD M Q H A N B1 (2R, 3R)
VbxI KR2 SAN G Q Y V N A1 S
VbxJ KR1 LAD L Q Y A N B1 R
proposed to be catalytically active; either during PKS assembly, or after chain
release. VbxA is a FADH2-dependent chlorinase that is proposed to chlorinate
C-11, and VbxB is a non-heme iron-dependent oxygenase that is proposed to
hydroxylate C-14.
4.6 Vibroxin loading module
4.6.1 HMM for starter MT
One remarkable di↵erence between vibroxin and enacyloxin is the methyl incor-
poration event in the loading module of each biosynthetic pathway. In both path-
ways, the loading modules are poorly annotated with current methods. HMMs
for MT domains that reliably identify other MTs within PKSs and NRPSs, are
ine↵ective at identifying the MT domain in VbxD (and Bamb 5925). Similarly,
other characterised examples of PKSs utilising an MT within a loading module
cannot be identified using the typical MT HMMs. Therefore, the amino acid
sequences corresponding to the dimerisation element (dMT) and the associated
MT upstream of the GNAT domain were used to build a novel HMM for N-
terminal starter MT domains (sMT). This was subsequently used to identify and
annotate examples of sMT-encoding genes within enacyloxin, saxitoxin, gephy-
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ronic acid and vibroxin gene clusters, as well as cryptic biosynthetic pathways
from a diverse range of organisms (Table. 4.3). These results exemplify the wider
occurrence of MT domains within PKS loading modules.
Table 4.3: Example of the diversity of domain organisation within degenerate
examples of sMT-containing proteins.
ID Domains in gene
WP 061546530.1 sMT-GNAT-ACP-Amino t
WP 061581925.1 sMT-GNAT-ACP-KS-KR-ACP-KS-DH-KS-KR-ACP-
KS-DH-ACP-KS-ACP
ABI91470.1 sMT-GNAT-ACP-KS-AT-DH-KR-ACP
ABK51302.1 sMT-GNAT-MT-ACP-KS-DH-ACP-KS-ACP-GNAT-
TE-KS
EEP93156.1 sMT-GNAT-KS-DH-KR-ACP
ADY62524.1 sMT-GNAT-ACP
CCF16272.1 sMT-ACP-KS-DH-KR
WP 011553948.1 sMT-GNAT-ACP-KS-KR-ACP
WP 017307890.1 sMT-GNAT-ACP-KS-AT-ACP
ERO59981.1 sMT-GNAT-ACP-KS-ACP-KS-DH-KR
WP 023131069.1 sMT-GNAT
AHA38199.1 sMT-GNAT-ACP-KS-AT-DH-MT-KR-ACP-KS-DH-
MT-KR-ACP
EYF04556.1 sMT-GNAT-ACP-KS-DH-KR-ACP-KS-DH-KR-ACP-
C-A-PCP
WP 027413074.1 sMT-ACP-ACP-KS-DH
WP 035684581.1 sMT-GNAT-ACP-KS-DH-KR-MT-ACP-KS-ACP-KS
WP 044619203.1 sMT-GNAT?-MT-ACP-KS-MT-ACP-ACP-KS-DH-
ACP-KS-KR-MT-ACP-KS-MT-ACP-KS-MT-ACP-
ACP-KS-KR-ACP-KS
WP 049974262.1 sMT-GNAT-ACP-KS-AT
WP 051908584.1 sMT-GNAT-ACP-ACP-KS-MT-ACP-TE
WP 052421794.1 sMT-GNAT-ACP-KS-ACP-ACP
KVD87326.1 sMT-GNAT-ACP-C-A-PCP-?-A-AT
XP 004991702.1 sMT-GNAT-ACP-KS-?-ER-KR-ACP-KS-AT-KR-
ACP-KS-KR-ACP-KS-KR-ACP-KS?
KYG81075.1 sMT
WP 060839246.1 sMT-GNAT-ACP-KS-ACP-Cy-Cy
WP 010587417.1 sMT-GNAT-ACP-KS-AT-DH-KR-ACP
Developing an HMM to describe sMT domains provides an e cient technique
for the identification of sMT domains from previously characterised biosynthetic
pathways (Fig. 4.11). Examples of natural products putatively utilising active
sMT domains are shown in Fig. 4.12. The basiliskamide PKS from Bacillus lat-
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erosporus (isolated from the ear of a feral hog)169 was identified as containing a
full sMT domain within the loading module, yet the final compound suggests that
an acetyl loading unit is incorporated. Presumably, the sMT is non-functional
within this biosynthetic pathway. However, a closely related analogue, YM-47522
from Bacillus sp. YL-03709B (soil isolate),170 is built from a propionyl starter
unit. Unfortunately, the genomic DNA sequence for YM-47522 biosynthetic gene
cluster is not currently available. Nevertheless, the presence of the additional
methyl group in YM-47522 is most likely derived from a functional form of the
sMT domain within its loading module. Whilst a nonfunctional sMT domain
is still present in the basiliskamide PKS, this may be an early step along the
evolutionary pathway to the full excision of this domain. If such processes are
genuine, uncovering biosynthetic pathways that display di↵erent stages of evolu-
tionary loss of sMT can act as ‘missing links’ to support this hypothesis. Whilst
the reverse process is possible, gaining sMT domains or sMT functionality poses
a significantly greater entropic expense.
Natural	product Methylation
rhizoxin 0
nosperin 0
kalimantacin 0
basiliskamide 0
psymberin 0
curacin 0
enacyloxin 1
saxitoxin 1
gephyronic acid 2
vibroxin 2
sMT HMM	coverage	and	relative	position
50	aa
Figure 4.11: Examples of biosynthetic pathways with characterised natural
products, displaying sMT coverage, and number of methylations from sMT.
The rhizoxin PKS171 contains an sMT domain within the loading module
of its biosynthetic pathway, yet no methylation activity is predicted to occur
at this stage. It is possible that a rhizoxin analogue exists resulting from a
biochemically active sMT domain, comparable to YM-47522 and basiliskamide.
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Figure 4.12: Natural products utilising sMT domains. Methylations predicted
to take place from MT domains within loading modules are displayed in red.
The sMT HMM also identified a slightly smaller sMT domain, with a relatively
low scoring homology, in the psymberin PKS. This is also presumed to be inactive
due to no methylation observed at the corresponding position in the molecular
structure of psymberin.
There are two characterised biosynthetic clusters which provide examples of
sMT excision during the course of biosynthetic evolution. The kalimantacin172
and nosperin173 PKSs both contain similar fragmented sMT domains within their
loading modules. Their N-termini contain a high scoring sMT fragment domain,
followed by a low scoring fragment of sMT. In both cases, the N-terminal region
of the sMT domain is not identified, and the C-terminal fragment exhibits very
low sequence conservation. No methylations take place during the biosynthesis
of these compounds. An example of a more truncated sMT domain can be found
within the curacin PKS, where the sMT domain predominantly consists of the
dMT subdomain and a minor fragment thereafter. This is also deduced to be
nonfunctional from the structure of curacin.
The sMT HMM has assisted with the identification of methyltransferase ac-
tivity within loading modules of di↵erent PKSs, and, as a result, o↵ers a common
74
explanation for propionyl and isobutyryl starter units found within PKSs with a
GNAT loading strategy. As with other PKS enzymes, sMT domains can appear
functional yet may be inactive, and inspection of motifs around putative SAM-
binding regions will o↵er more insight. Care must also be taken when identifying
sMT fragments which are likely to be non-functional. However, these o↵er a valu-
able perspective on the evolution of starter units within biosynthetic pathways,
and the potential for historic or unidentified analogues.
4.6.2 Feeding of (13C-Me)-L-methionine
The sMT domain that was identified in VbxD, from the vibroxin biosynthetic
pathway, is proposed to perform two methylations within the loading module.
This dimethylation activity was probed by feeding (13C-Me)-l-methionine to V.
rhizosphaerae, to evaluate the number of 13C-methyl groups incorporated into vi-
broxin (Fig. 4.13a). The labelled methionine is metabolised by V. rhizosphaerae
to form S-adenosyl-methionine (SAM), the cofactor for sMT domains. Subse-
quently, 13C-methyl groups are incorporated during vibroxin biosynthesis for each
SAM-dependent methylation. Three MT domains are present in the vibroxin
biosynthetic pathway, within VbxG, VbxI, and VbxD, which is proposed to act
twice. Therefore, the incorporation of four 13C atoms is predicted during vibroxin
biosynthesis, when feeding V. rhizosphaerae with (13C-Me)-l-methionine.
Ethyl extracts were performed from V. rhizosphaerae fed with natural abun-
dance methionine (Fig. 4.13bi) and (13C-Me)-L-methionine (Fig. 4.13bii). Incor-
poration of the isotope precursor was observed at 90% for all of the proposed
SAM-derived methyl groups within vibroxin. An estimated 73% of vibroxin
molecules are shown to contain four 13C atoms, 20% contained three 13C atoms,
and less than 7% contained fewer than three 13C atoms. Together, this ensemble
describes the isotopic MS distribution observed in Fig. 4.13bii. The incorporation
of four labelled methyl groups supports the proposed dimethylation of the starter
unit by the sMT domain within VbxD.
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Figure 4.13: a) Schematic of isotopic incorporation of 13C from (13C-Me)-l-
methionine into vibroxin, where the sites of incorporation are shown in red circles.
b) Isotopic MS distribution for vibroxin from V. rhizosphaerae fed with i) natural
abundance methionine, or ii) (13C-Me)-l-methionine.
4.7 Antimicrobial activity
Vibroxin possesses a similar molecular structure to enacyloxin IIa, a well-known
antibiotic that is active against A. baumannii and inhibits elongation factor Tu
(EF-Tu), an essential component of the bacterial protein synthesis machinery.
A. baumannii is an opportunistic human pathogen that is highly resistant to most
antibiotics in clinical use and causes hospital-acquired infections in people with
compromised immune systems.3 Current antibiotic treatments for A. bauman-
nii are progressively becoming ine↵ective as resistance develops. The resistance
rates for antibiotics that are no longer viable as treatment options are listed in
Table 4.4.
Table 4.4: Resistance rates of A. baumannii to antibiotics.174
Antibiotic Resistance rate (%)
ciprofloxacin 32-100
cefepime 91-100
piperacillin-tazobactam 90-92
amikacin 24-94
gentamicin 18-85
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The current solution is to use colistin in combination with rifampicin, sulbac-
tam and carbapenems. However, colistin is nephrotoxic and resistance to it is
reported world-wide (although currently only at relatively low levels (2%) in A.
baumannii).174 The development of novel antibiotics with potent activity against
A. baumannii, such as enacyloxin analogues, is necessary to combat nosocomial
infections. To verify whether vibroxin has an analogous antimicrobial spectrum
of activity to enacyloxin IIa, a series of antimicrobial assays were designed with
V. rhizosphaerae and purified vibroxin.
4.7.1 Whole cell activity
Activity of V. rhizosphaerae was tested using overlay experiments by monitoring
the size of inhibition zones arising from growth of a spotted colony of V. rhi-
zosphaerae on a lawn of pathogenic bacteria. V. rhizosphaerae was shown to
exhibit broad spectrum activity against a range of organisms including Gram-
positive and Gram-negative bacteria (Fig. 4.14). The most potent activity was
observed against B. multivorans and A. baumannii. This whole cell activity as-
say tests all compounds produced by V. rhizosphaerae, including the bioactive
prodigiosin. To assess the potency of vibroxin alone, assays were also performed
with purified vibroxin.
MRSA
B.	subtilis E.	cloacae
S.	plymuthica
K.	pneumoniae
B.	multivorans
A.	baumannii
C.	albicans
Figure 4.14: Overlay antimicrobial assays with V. rhizosphaerae and pathogenic
bacteria.
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4.7.2 Vibroxin MIC
The quantitative determination of antimicrobial activity is necessary to evaluate
antibiotic potency across di↵erent pathogenic strains. One method of clinical sig-
nificance is the minimum inhibitory concentration (MIC) assay using the Clinical
Laboratory and Standards Institute (CLSI) broth micro-dilution method. The
lowest concentration that inhibits bacterial growth is visually determined for vi-
broxin following an overnight incubation. The MIC for vibroxin was determined
against six representative pathogens with growing multi-drug resistant virulence,
i.e. the ‘ESKAPE’ panel (Table 4.5). Vibroxin was shown to demonstrate potent
activity against A. baumannii with a MIC of 2 µg/mL (cf. 2 µg/mL for enacy-
loxin IIa). The growth of all other tested pathogens was not inhibited by vibroxin
below the maximum concentration tested. Whilst the MIC value relates to growth
inhibition, the minimal bactericidal concentration (MBC) represents the lowest
concentration of a bioactive compound required to kill a particular pathogen. The
MBC was determined to be 8 µg/mL for vibroxin against A. baumannii which
lies on the boundary of what is considered bactericidal or bacteriostatic.
Table 4.5: MIC and MBC values for vibroxin determined against the ESKAPE
panel of pathogens.
Organism MIC (µg/mL) MBC (µg/mL)
Enterococcus faecium >32 >32
Staphylococcus aureus >32 >32
Klebsiella pneumoniae >32 >32
Acinetobacter baumannii 2 8
Pseudomonas aeruginosa >32 >32
Enterobacter cloacae >32 >32
4.8 Conclusion and further work
Genome mining of V. rhizosphaerae led to the targeted discovery of the antibi-
otic vibroxin, revealing the value of rhizosphere-associated Vibrio as a source of
natural products. The vibroxin biosynthetic gene cluster reveals insights into the
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evolution of the homologous enacyloxin biosynthetic gene cluster. In particular,
how genetic inversion events and excisions have left relics in terms of domain frag-
ments. A number of di↵erences between the enacyloxin and vibroxin biosynthetic
pathways have not yet been fully explained. Whilst VbxJ contains an additional
KR domain, compared to Bamb 5920, both biosynthetic pathways display KR
function at this stage. The origin of the KR enzymatic function in enacyloxin
biosynthesis therefore remains unknown. A dehydration event is predicted to take
place in the second module of the vibroxin PKS, yet no DH domain is present
within VbxE. The underlying mechanism of this di↵erence between vibroxin and
enacyloxin is still unclear.
The development of an HMM to identify sMT domains assists with the an-
notation of any PKS gene utilising this type of domain. This HMM can provide
valuable insight when predicting core molecular structures of putative polyketides,
and has uncovered indications of evolutionary development of loading modules
within PKSs. The basis for methylation control by sMT domains has not been
elucidated in terms of predicting the number of methylations of a starter unit, but
provides an opportunity for engineering starter units within biosynthetic path-
ways utilising a GNAT-based loading strategy.
The potent antimicrobial activity of vibroxin against the opportunistic pathogen
A. baumannii highlights the value of targeted drug discovery using a genomics-
driven approach. Vibroxin is potentially more exploitable for semi-synthesis or
total chemical synthesis due to a simplified molecular structure compared with
enacyloxin, and is chemically more stable. Novel molecular features or fragments
could be utilised as a reference on which to design more potent, stable vibroxin
analogues via biosynthesis or chemical synthesis. The stereochemistry of the
hydroxyls in the polyketide chain, and the proximal methyl (C-12 to C-17), is
proposed based upon KR stereospecificity, but experimentally determined stereo-
chemistry is required, which may be achieved from NMR spectroscopy of vibroxin
derivatives or comparison with chemically synthesized standards.
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Chapter 5
Materials and Methods
5.1 Materials
5.1.1 Plasmids
Constructs for the expression of domains from the enaclyoxin biosynthetic path-
way were provided by Dr P Sydor (University of Warwick), and those encoding
watasemycin NRPS domains were provided by S Zhou (University of Warwick),
within the pET151 plasmid; these are listed in Table 5.1. The plasmid containing
sfp was acquired from Manuela Tosin (University of Warwick) in pET28b.
Table 5.1: Plasmids for protein production.
Protein domain names Gene name Length (bp)
PCP-COM2C bamb 5917 405
ACP bamb 5919 660
COM2N -C bamb 5915 1638
KS0 bamb 5919 2156
PCP-COM2C sven 0512 453
Sfp sfp B. subtilis -
5.1.2 Microbial Strains
High transformation e ciency, and plasmid propagation, was achieved using
Top10 Escherichia coli (Invitrogen). For protein production, E. coli strains
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BL21 (DE3) (Invitrogen) and C43 (DE3) (Invitrogen) were used. Vibrio rhi-
zosphaerae MSSRF3 (DSM 18581) was used for vibroxin production. Bioactivity
assays using V. rhizosphaerae or vibroxin were performed using the following
organisms:
• Bacillus subtilis
• Methicillin-resistant Staphylococcus aureus DSM 21979
• Staphylococcus aureus NCTC 12981
• Escherichia coli SY397
• Serratia plymuthica RVH1
• Pseudomonas aeruginosa DSM 29239
• Burkholderia multivorans ATCC 17616
• Klebsiella pneumoniae DSM 26371
• Enterobacter cloacae DSM 16690
• Acinetobacter baumannii DSM 25645
• Candida albicans SC 5314
• Enterococcus faecium DSM 25390
5.1.3 Culture media
Lysogeny broth (LB) (Fisher), tryptic soy broth (TSB) (Fisher) and basal salt
medium (BSM),175 were made following the suppliers recommended dilutions.
Glycerol or glucose was used as a carbon source for BSM media to a final con-
centration of 4 g/L.
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M9 minimal media
5 ⇥ M9 salt solution
• 32 g Na2HPO4.7H2O
• 6 g KH2PO4
• 2.5 g NaCl
• Add H2O up to 500 mL and autoclave
M9 minimal media
• 200 mL 5 ⇥ M9 salt solution
• 2 mL of 1 m MgSO4
• 100 µL of 1 m CaCl2
• Add H2O up to 1 L and autoclave
• 2 g of d-13C-glucose (or 4 g of d-glucose) in 20 mL H2O with 0.2 µm
filtration
• 20 mL of 100 ⇥ BME vitamins (Sigma Aldrich)
• 0.5 g of 15NH4Cl in 2.5 mL H2O with 0.2 µm filtration
• Ampicillin (final concentration 50 µg/mL)
5.2 Molecular Biology
5.2.1 Site-directed mutagenesis
For single, double and truncation mutations, the Q5 site-directed mutagenesis kit
(NEB) was used. Primers were designed using the associated NEBaseChanger
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tool, where truncation mutants were achieved through substitution mutants us-
ing the TGA stop codon. Annealing temperatures, PCR protocols, Kinase-
Ligase-DpnI (KLD) reactions, and transformations were conducted according to
suppliers guidelines. Typically, three colonies were selected for plasmid isola-
tion using the GeneJET Plasmid Miniprep Kit (Thermo Scientific). DNA con-
centration was measured by absorbance at 280 nm. Resulting plasmids were
confirmed by DNA sequencing. The primers used for site directed mutagene-
sis were: PCP  9 f = GGCGCCTTCGGGCGACCAGGACGATGCATGAGAG-
TACGAAGAAGGCGTGATCC, PCP  9 r = CCGCGGAAGCCCGCTGGTC-
CTGCTACGTACTCTCATGCTTCTTCCGCACTAGG.
5.2.2 Sequencing
Sanger sequencing (GATC-biotech) was used to determine successful mutations
of genes within the pET151 plasmid. Samples were prepared according to the
company’s requirements. Sequencing primers were T7 forward primer and pET-
RP reverse primer.
5.2.3 Preparation of chemically competent E. coli
A glycerol stock of E. coli (e.g. Top10, BL21*, C43) was used to inoculate 10
mL of LB (Lysogeny broth) and grown overnight at 37  C at 180 rpm. 1 mL
of preculture was used to innoculate 100 mL of LB. This was grown at 37  C,
180 rpm until OD600 nm=0.6. Cells were recovered by centrifugation at 2057 g
for 7 minutes at 4  C. The pellet was resuspended by gentle mixing in 20 mL of
chemically competent E. coli washing bu↵er (80 mm MgCl, 20 mm CaCl2). Cells
were then centrifuged as previously described. The supernatant was decanted and
the pellet was resuspended in 1 mL of cold 0.1 M CaCl2. For each transformation
50 µL of cells were used. For long term storage cells were flash frozen and stored
at -80  C.
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5.2.4 Transformation of chemically competent E. coli
For each transformation, 1 µL of the DNA construct (100 ng/µL) was gently
mixed with 50 µL of chemically competent E. coli on ice. The mixture was
incubated on ice for 30 minutes, transferred to a 42  C water bath for 90 seconds,
then left to rest on ice for 2 minutes. 200 µL of pre-warmed LB or super optimal
broth with catabolite repression (SOC) was added to the cells and they were
incubated at 37  C, 180 rpm for 1 hour. Transformants were selected by plating
the culture on LB agar plates with a relevant antibiotic. Plates were incubated
at 37  C overnight.
5.3 Protein production
5.3.1 Recombinant protein production
A colony from a successful transformation was isolated from a plate to inoculate
5 mL of LB and a relevant antibiotic (at final concentrations of 100 µg/mL
ampicillin or 50 µg/mL kanamycin). The 5 mL culture was grown overnight
at 37  C, 180 rpm. The overnight culture was used to inoculate a flask of LB
(typically 1 L) supplemented with an antibiotic selection marker. The culture
was grown at 37  C at 180 rpm until OD600 nm=0.6, then cooled to 4  C. A sterile
solution of isopropyl  -d-1-thiogalactopyranoside (IPTG) was added to a final
concentration of 0.5 mm, and the culture was left at 15  C, 180 rpm overnight.
5.3.2 Recombinant protein production - isotope labelling
A 1 L culture of cells was grown in LB supplemented with an antibiotic until
OD600 nm=0.6. This culture was inoculated from an overnight culture as pre-
viously described. Cells were harvested by centrifugation (6080 g, 20 minutes,
4  C), washed once with 200 mL of M9 sterile salt solution and centrifuged (6080 g,
20 minutes, 4  C) thereafter. The pellet was resuspended in 1 L of M9 minimal
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media with 15N labelled 15NH4Cl as the sole nitrogen source, d-13C-glucose as
the only carbon source (or natural abundance glucose), supplemented with an
antibiotic and IPTG (0.5 mm). The culture was incubated overnight at 20  C,
180 rpm.
5.3.3 Purification of recombinant histidine-tagged proteins
Cells from the overnight culture (natural abundance or isotopically labelled) were
centrifuged at 6080 g for 20 minutes. The pellet was resuspended in 10 mL
of wash bu↵er (20 mm Tris-HCl pH 8, 100 mm NaCl, 10% glycerol, 20 mm
imidazole) and phenylmethylsulfonyl fluoride (PMSF) per 1 L culture. Cell lysis
was performed using a cell disruptor in one shot mode at 20 kpsi. The lysate
was centrifuged at 38720 g for 20 minutes at 4  C. The supernatant was filtered
(0.22 µm) and purified using an A¨kta purifier and a 1 mL (or 5 mL) HiTrap HP
a nity column (Nickel Sepharose High Performance, GE) at 4  C. The column
was equilibrated with washing bu↵er. Unbound proteins were removed using
washing bu↵er, and His-tagged proteins were eluted with a gradient application
of elution bu↵er (20 mm Tris-HCl pH 8, 100 mm NaCl, 10% glycerol, 300 mm
imidazole). An additional purification step of gel filtration chromatography was
carried out when necessary using either a Superdex 200 10/300 or Superdex 75
16/600 columns, with a gel filtration bu↵er (20 mm Tris-HCl pH 8, 100 mm
NaCl). Fractions were collected and concentrated using Amicon Ultra filters with
a 3,000 10,000 or 30,000 kDa molecular weight cuto↵ membrane (Millipore) in a
concentration bu↵er (20 mm Tris-HCl pH 8, 100 mm NaCl, 10% glycerol). Any
subsequent exchanging of bu↵er was performed using PD-10 desalting columns
(GE) using the gravity method or HiTrap desalting columns (GE) with an A¨kta
purifier. Proteins were analysed by sodium dodecyl sulfate-polyacrylamide gel
electrophoresis (SDS-PAGE),176 and were stored at -80  C. The protein standards
ladder used for SDS-PAGE at with the following molecular weights in kDa: 10
(green), 15, 25 (red), 35, 55, 70 (red), 100, 130 and 250. Protein concentration
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was calculation by absorbance at 280 nm using predicted extiction coe cients.177
5.4 Protein NMR spectroscopy
5.4.1 Sample preparation
Concentrated proteins were exchanged from the concentration bu↵er to 50 mm
potassium phosphate, 150 mm NaCl pH 6.5 (supplemented with 50 mm Arg,
50 mm Glu for assignment sample) via a PD-10 desalting column (GE). After
bu↵er exchange, the proteins were concentrated as previously described. For
locking, 5% D2O was added, and 40 µm 4,4-dimethyl-4-silapentane-1-sulfonic
acid (DSS) was included.
5.4.2 PCP assignment
NMR experiments were acquired at 288 K on Bruker Avance II 700 MHz equipped
with 5 mm triple-resonance 1H{13C/15N}, pulse-field gradient carbon optimised
cyroprobe. PCP17-COM2C backbone assignment was carried out using the suite
of standard Bruker 3D pulse programs (HN(ca)CO, HN(co)CA, CBCA(co)NH).
Side-chain resonances were assigned using HCCH-TOCSY/COSY, HBHA(co)NH,
H(CCCO)NH and verified using 3D 1H- and 13C-filtered NOESY. Assignment was
performed with 500 µm [U-13C,15N]PCP-COM2C in 50 mm phosphate, 50 mm
arginine, 50 mm glutamine, 50 mm NaCl, 5% D2O, 2 mm TCEP, 40 µm DSS at
288 K. Data was processed in Topspin and exported to NMRFAM-Sparky178 for
further analysis. Resonances were picked automatically and manually edited.
Predicted assignments were performed using PINE179 and were confirmed or
edited accordingly.
5.4.3 Protein interactions by NMR
For each concentration point during a protein-protein interaction experiment a
new sample was made (from the same protein stock) to circumvent dilution e↵ects
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and bias during signal acquisition and data processing. Signal intensities were
calculated in NMRFAM-Sparky for backbone amides. For PCP and C domain
interaction experiments, each sample contained 250 µm of labelled carrier protein,
with varying amounts of unlabelled condensation domain in 50 mm potassium
phosphate, 150 mm NaCl pH 6.5, 5% D2O and 40 µm DSS.
5.5 Biochemical assays
5.5.1 Carrier protein acetylation
Apo-carrier proteins (apo-CPs) were posttranslationally modified to holo-CPs
(or acetyl-CPs) using a phosphopantetheinyl transferase (PPTase) Sfp from B.
subtilis and a coenzyme A (or acetyl-CoA). The reaction was performed using
200 µm CP, 10 µm Sfp, 0.5 mm acetyl-CoA (or CoA for holo-CP), 12.5 mm
MgCl2, 2 mm TCEP, 100 mm Tris pH 7.5. The reaction was incubated at 30
 C for 90 minutes and monitored by matrix-assisted laser desorption/ionization
time-of-flight (MALDI-ToF) or liquid chromatography–mass spectrometry (LC-
MS).
5.5.2 Condensation assay
The COM2N -C catalysed condensation of acetyl-PCP-COM2C (or acetyl-PCP)
and shikimate, was carried out with 200 µm acetyl-PCP-COM2C incubated with
20 µm COM2N -C and 1.5 mm shikimate overnight at 30  C. Reactions were
stopped by adding two volume equivalents of MeOH to the reaction. Centrifu-
gation and filtration was performed before analysis by MaXis Impact to detect
small molecules. The LC elution profile is outlined in Table 5.2 at 0.2 µL/min
flow rate using the same column as for natural product extracts.
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Table 5.2: LC-MS elution profile for condensation assay product detection.
Time (minutes) H2O % (0.1% FA) Acetonitrile % (0.1% FA)
0 95 5
5.3 95 5
17.3 0 100
22.6 0 100
25.3 95 5
34 95 5
5.6 Vibroxin from V. rhizosphaerae
5.6.1 Natural product extraction
Vibrio rhizosphaerae DSM 18581 was acquired from Leibniz Institute DSMZ
(German Collection of Microorganisms and Cell Cultures). Growth of V. rhi-
zosphaerae was performed in TSB2S (tryptic soy broth supplemented with 2%
NaCl) or BSM2S (basal salt medium supplement with 2% NaCl), in liquid and
on solid media. For vibroxin production, V. rhizosphaerae was grown on solid
BSM2S media and incubated at 30  C for 65 hours. V. rhizosphaerae was re-
moved from BSM2S-agar plates and the BSM2S-agar was cut into small pieces.
Ethyl acetate was added to cover the BSM2S agar and left to stand for 1 hour
before filtering the extract, and concentrating in vacuo. The extract was solu-
bilised in acetonitrile for detection by LC-HR/MS. A ZORBAX Eclipse Plus C18
column 1.8 µm, 2.1 ⇥ 100 mm (Agilent) was used following the elution profile
from Table 5.3 with a 0.2 µL flow rate. The absorbance was measured at 360 nm
corresponding to the unsaturated/diene molecular constituents. Data was in-
ternally calibrated using sodium formate and molecular formulae were predicted
using DataAnalysis.
5.6.2 Bioactivity using whole cell
A fresh culture of V. rhizosphaerae, grown on TSB2S-agar, was isolated with
a loop and resuspended in 4 mL of 0.9% NaCl. From this solution, 5 µL was
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Table 5.3: LC-MS elution profile for natural product extracts.
Time (minutes) H2O % (0.1% FA) Acetonitrile % (0.1% FA)
0 70 30
5.3 70 30
17.3 0 100
22.6 0 100
25.3 70 30
34 70 30
spotted in the centre of each TSB2S-agar plate and incubated at 30  C for 65
hours. Spotted V. rhizosphaerae cultures were killed using chloroform vapour.
Glycerol stock cultures of Escherichia coli SY327, Burkholderia multivorans and
Staphylococcus aureus (add ESKAPE) were used to inoculate 5 mL of TSB media
and incubated overnight at 30  C. From each culture, 15 µL was taken and diluted
in 15 mL of LB-soft-agar supplemented with 2 mg of 2,3,5-triphenyltetrazolium
chloride (TTC). For each plate, 7.5 mL of this mixture was spread evenly to
create a lawn for overnight incubation at 30  C.
5.6.3 Vibroxin isolation and purification
Large scale solid BMS-agar cultures were performed as previously described for
natural product extraction using eighty 15 mL plates. Extraction with ethyl
acetate, filtering, and concentration was repeated twice. During and after extrac-
tion, light contact was minimised to deter isomerisation of the natural product.
The extract was filtered and purified by analytical HPLC with using a ZORBAX-
SB C18 column (21.2 ⇥ 100 mm, 5µm) following the elution profile from Table 5.4
monitoring the absorbance at 360 nm. Fractions from multiple runs were pooled,
concentrated in vacuo, and subsequently lyophilized.
5.6.4 Vibroxin characterisation by NMR
Purified vibroxin was dissolved in 150 µL d4-MeOH whilst minimising light expo-
sure. 1D 1H, 2D 1H-1H COSY, 1H-13C HSQC, 1H-13C HMBC and 1H-1H NOESY
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Table 5.4: HPLC elution profile for vibroxin purification.
Time (minutes) H2O % (0.1% FA) Methanol % (0.1% FA)
0 30 70
2 30 70
5 15 85
30 0 100
32 0 100
36 30 70
40 30 70
experiments were recorded using standard procedures at 288 K on a 500 MHz
Bruker Avance III HD spectrometer with a DCH cryoprobe. NOESY mixing
times were 30 and 100 ms. The obtained spectra are reproduced in the Appendix
Fig. 7.15-7.19.
5.6.5 Feeding experiments
Feeding experiments were performed for V. rhizosphaerae grown on BMS2S-
glycerol-agar (basal salt medium with glycerol as the primary carbon source,
supplemented with 2% NaCl) containing 10 mm (13C-methyl)-l-methionine. Each
culture was grown on 10 mL of media. A subset of V. rhizosphaerae cultures
were subjected to feeding of a saturated (13C-methyl)-l-methionine solution, dis-
tributed by spotting 5 µL upon the culture after 18 and 42 hours of incubation
at 30  C. After three days, ethyl extracts were performed from solid media using
20 mL of ethyl acetate for each 10 mL culture before concentration in vacuo.
Extracts were solubilised in acetonitrile/water 70/30 for analysis by LC-HR/MS.
The LC-MS protocol was the same as for other V. rhizosphaerae extracts as
described in Section 5.6.1.
5.6.6 M.I.C measurement
The ESKAPE panel were grown overnight in Mu¨ller-Hinton (MH) media at 30  C
overnight. Each organism was diluted to a final concentration of 5 ⇥ 105 colony-
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forming units/µL using McFarlands turbidity standards.
5.6.7 M.B.C. determination
The minimum bactericidal concentration (MBC) was determined for vibroxin by
subculturing from the MIC assay to LB-agar plates without vibroxin.
5.7 Computational
5.7.1 Hidden Markov models
Hidden markov models (HMMs) for a number of PKS and NRPS domains were
acquired from antiSMASH 3.0180, and others were acquired from Pfam. Novel
HMMs were built from manually curated sequences aligned using clustalw2 and
developed using HMMER 3.1b2181. Searches using HMMs were also carried out
using this software.
5.7.2 PKS/NRPS sequence databases
Sequences used for terminal motif identification were scraped from ClusterMine
360 from which a subset of clusters were used to form the basis of a database
of PKS/NPRS sequences. Individual clusters of interest were added manually
thereafter. As a test data set, sequences were downloaded from an atlas of PKS
and NRPS sequences used for testing novel HMMs.
5.7.3 Peptide binding simulation
CABS-Dock182 was used for peptide-protein interactions for COM2C with COM2N .
The C-terminal COM2C domain was evaluated with the isolated COM2N domain
as the peptides binding target. The CABS-dock procedure utilizes Replica Ex-
change Monte Carlo dynamics with 10 replicas uniformly spread on the temper-
ature scale using randomised initial peptide structures.182
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Chapter 6
Conclusions
6.1 Summary and outcomes
6.1.1 Objective I review
A biophysical basis for chain release in the enacyloxin PKS-NRPS has been de-
scribed in the form of COM domains, across the PCP and C domain protein
boundary. A protein complex model of PCP-COM2C and COM2N -C provides a
representation of the intermolecular interaction. This presents a picture of the
accessibility of PCP, to receive substrates from the previous domain, and to do-
nate substrates to the C domain, in a recursive procedure, whilst maintaining
complex formation with COM domains.
The type 2 COM domain interaction, observed in enacyloxin PKS-NRPS, was
extended to many other characterised NRPS and hybrid PKS-NRPS biosynthetic
pathways. This was possible due to the development of a HMM to describe
COM2N domains, and the curation of a PKS/NRPS database. Investigating
characterised and cryptic biosynthetic pathways revealed a degree of variation in
the enzymatic domains found adjacently to COM domains. The corresponding
COM2C interaction partners displayed conservation in an EExxL motif, which
was consistent with interaction sites on PCP-COM2C (within Bamb 5917 from
enacyloxin PKS) using protein NMR spectroscopy. Subsequently, biochemical
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assays showed that the COM2C domain was necessary for e cient catalysis, and
the non-native PCP-COM2C (within Sven 5012) from watasemycin NRPS could
facilitate catalysis with the COM2N -C didomain (within Bamb 5915) from enacy-
loxin PKS-NRPS. This demonstrates the inherent promiscuity for this particular
pair of COM domains.
The abundance of type 2 COM domains lead to the critical evaluation of
a tool for identifying type 1 COM domains and docking domains. Investiga-
tions of terminal amino acid sequences from PKS and NRPS proteins led to new
HMMs, to identify previously unidentified features from characterised biosyn-
thetic pathways. The use of HMMs, to describe docking domains, also led to the
identification of docking domains that were not located at protein termini. An
observation from a collection of N-terminal DH domains led to the proposal of a
novel form of intermolecular interaction. A C-terminal interaction peptide was
proposed to interact directly with the DH domain. This domain was described
using a HMM, which appeared to identify DH domains, where an ACP-bound
(2E,4Z)-configured diene produced by the same module.
6.1.2 Objective II review
The genomics-driven search for enacyloxin analogues led to the identification
of a homologous biosynthetic gene cluster within V. rhizosphaerae. The pro-
duction of the enacyloxin analogue, vibroxin, was optimised, extracted, puri-
fied and structurally characterised. A narrow spectrum of antimicrobial activity
was observed, with potent antimicrobial activity against the multi-drug resistant
pathogen A. baumannii.
The core molecular structure of vibroxin exhibited some features that were
not predicted from the biosynthetic gene cluster. Namely, the dimethylation of
the starter unit, and a dehydration event corresponding to the second extension
module. Together, this formed a proposed biosynthetic pathway for the antibiotic
vibroxin. An HMM was built to describe sMT domains within loading modules.
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This facilitated their annotation within PKS proteins. Subsequently, fragments
of sMT domains were identified within characterised biosynthetic pathways. This
uncovered pieces of PKS evolution where enzmye activity is lost, and domains are
partially excised. Similarly, fragments of AT domains were also identified within
vibroxin PKS-NRPS and enacyloxin PKS-NRPS.
6.2 Context and outlook
The widespread use of docking domains and COM domains, to facilitate biosyn-
thesis across protein boundaries, provides new opportunities to exploit these fea-
tures to engineer biosynthetic pathways. Not only are type 2 COM domains
involved in the biosynthesis of enacyloxin and vibroxin, but they present a com-
mon form of intermolecular interactions within biosynthetic pathways. These in-
termolecular interactions direct the biosynthesis of antibiotics, antifungal agents,
insecticides, protease inhibitors, biosurfactants and cannabinomimetics from a di-
verse genera of producing organisms. Cryptic biosynthetic clusters indicate more
diverse biochemistry across COM-junctions. Thus, providing opportunities for
targeted intermediate tailoring during thiol-template biosynthesis, and chain re-
lease mechanisms, represented by thioesterases, thioester-reductases, halogenases
and methyltransferases.
The identification of putative C-terminal docking peptides across a set of KS
and DH domain boundaries, would benefit from in vitro biophysical and bio-
chemical analyses from an isolated system. Similarly, the mechanism of putative
(2E,4Z)-configuring DH domains from characterised biosynthetic pathways could
be probed experimentally. Furthermore, a demonstration of the predictive e -
cacy of the (2E,4Z)-DH HMM, would be to identify this domain within a cryptic
biosynthetic gene cluster, and investigate the configuration of a corresponding
diene.
The discovery of antibiotic vibroxin is a testimony to genomics-driven ap-
proaches for bioactive natural product discovery. It also highlights the untapped
94
potential of natural products from rhizosphere-associated Vibrio. Whilst a pre-
dicted core molecular structure assisted with the identification of vibroxin, exper-
imental characterisation revealed the limitations of current predictive tools, and
our understanding of modular PKSs. The identification of sMT domains within
cryptic biosynthetic clusters will increase this predictive e cacy. The identifica-
tion of inactive sMT domains, sMT fragments, AT fragments, and KS fragments
demonstrates consequences of blind evolution. It is convenient to regard combina-
torial biosynthetic pathways as collections of modular building blocks, susceptible
to rearrangement. However, it is a misconception to interpret nature’s biosyn-
thetic pathways as rational designs. As a consequence, domain fragments, inactive
domains (or partially active domains e.g. KS0) and unusual domain architectures
should be viewed with appreciation of their evolutionary development.
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Chapter 7
Appendix
7.1 Sequences of PKS and NRPS domains
>Bamb 5919 ACP aa
MHHHHHHGKPIPNPLLGLDSTENLYFQGIDPFTLAELVEAEAGATGASG
APRVERRAGGTAGAALLAGLASLDAAARAARLKRHLEAAIRKLLNRADT
LDDRASMFDLGLDSLLSIDLRMQLEKDLACSLSTTVLHDHPTIEALAGFLA
ERVGAPPAGTVRAGAAGGAGAGTGAPAGATGAAAAHAVSSASPVPAG
AASAAASAASAAAAAGAPSRATFA
>Bamb 5919 ACP dna
ATGCATCATCACCATCACCATGGTAAGCCTATCCCTAACCCTCTCCT
CGGTCTCGATTCTACGGAAAACCTGTATTTTCAGGGAATTGATCCCT
TCACCCTGGCCGAGCTGGTCGAGGCCGAGGCAGGCGCGACGGGCGC
GAGCGGAGCACCGCGCGTCGAGCGCCGCGCCGGCGGCACGGCCGGC
GCGGCACTGCTGGCGGGCCTCGCGAGCCTCGATGCGGCGGCGCGCG
CGGCGCGCCTGAAGCGCCATCTCGAGGCCGCGATCCGCAAGCTGCTC
AACCGCGCCGATACGCTCGACGATCGCGCCAGCATGTTCGATCTCGG
TCTCGATTCGCTGCTCAGTATCGACCTGCGCATGCAGCTCGAGAAGG
ACCTGGCCTGCAGCCTCTCGACCACGGTGCTGCACGACCATCCGACC
ATCGAGGCGCTGGCGGGCTTCCTGGCCGAACGCGTGGGTGCGCCGC
CGGCGGGGACGGTTCGCGCAGGGGCCGCGGGCGGTGCCGGTGCAGG
CACCGGCGCGCCTGCCGGCGCCACTGGGGCCGCGGCTGCGCATGCC
GTATCGTCGGCCTCGCCCGTGCCGGCCGGGGCCGCGTCGGCCGCTG
CATCCGCTGCATCCGCTGCAGCGGCAGCCGGCGCCCCGTCGCGCGCC
ACGTTCGCG
>Bamb 5919 KS0 aa
MHHHHHHGKPIPNPLLGLDSTENLYFQGIDPFTPSRATFAAEPRRAGGA
ALPPGAGPDDIAIIGVSGRYPGAADLGAFWDNLRDGHDAITPIPPERWN
HDAYFDRQRNVPGKSYSAWGGFIEDVDAFDPAFFSISPRMSAYLDPKER
LFLETVWNLLEEAGETRERMQQAYGAQVGVFVGAMYQLYGACAADEG
ERVATALSSYNAIAHRTSYFFNLRGPSIALDTMCSSSLTAVHYACRSLLDG
DCALAIAGGVNLSLHPRKYVGLSQAQIVGSHADSRSFSDGDGYLPAEGVG
AVLLKPLARALADDDRILAVIKASSVNHGGRATGYYAPNANAQVDLMEA
SFRKAGVSPESIDYIEAAANGTSLGDAVELRALARVFDGTARDGRRVPIG
110
TVKSNIGHPEAASGIAQLTKVILQMQHETLVPSIKTEPVNPNLDLAHTPFR
LLSRQAAWPSDPARPRRATVSSFGASGANAHLIVEAFETVEAEPAPAVA
QAAPPAEIVVLSARTPAQLREVARRLLAWLATRQAAGRAESAVPLAERG
RACSLANLAHTLQIGREAMDCRLALLADSLDTLGDGLRRFLGESAGAAE
PAIYHGNVQDQLEMRNLLAGAAGDAMAQTLVAERNLEGLMLHWVQGG
NVPWAALREGRPARRLVLPTYPFERERYWLSGASDAAGRGAGEPQVPA
EPAEAASEPSVVDGRA
>Bamb 5919 KS0 dna
ATGCATCATCACCATCACCATGGTAAGCCTATCCCTAACCCTCTCCT
CGGTCTCGATTCTACGGAAAACCTGTATTTTCAGGGAATTGATCCCT
TCACCCCGTCGCGCGCCACGTTCGCGGCCGAGCCGCGTCGTGCCGGC
GGCGCGGCGCTGCCGCCCGGCGCCGGCCCCGACGACATCGCCATCAT
CGGCGTATCGGGCCGCTACCCCGGCGCGGCCGACCTCGGCGCGTTCT
GGGACAACCTGCGCGACGGCCACGACGCGATCACCCCGATCCCGCCC
GAGCGCTGGAACCACGACGCCTACTTCGACCGGCAGCGCAACGTGCC
CGGCAAGAGCTACAGCGCCTGGGGCGGCTTCATCGAGGACGTCGAC
GCCTTCGACCCGGCCTTCTTCAGCATCTCGCCGCGGATGTCGGCCTA
CCTCGATCCGAAGGAGCGGCTGTTCCTCGAGACGGTCTGGAACCTGC
TGGAGGAGGCGGGCGAGACGCGCGAGCGCATGCAGCAGGCCTATGG
CGCGCAGGTGGGCGTGTTCGTCGGCGCGATGTACCAGCTCTATGGC
GCCTGCGCGGCCGACGAGGGCGAGCGCGTGGCCACCGCGCTGTCCT
CCTACAACGCGATCGCGCATCGCACCTCGTACTTCTTCAACCTGCGC
GGGCCGAGCATCGCGCTCGACACAATGTGCTCGTCGTCGCTGACGG
CGGTCCACTACGCCTGCCGCAGCCTGCTCGACGGCGACTGCGCGCTG
GCCATCGCGGGCGGCGTGAACCTGTCGCTGCATCCGCGCAAGTACG
TCGGGCTGAGCCAGGCGCAGATCGTCGGCAGCCATGCCGACAGCCG
CAGCTTCAGCGACGGCGACGGCTACCTGCCGGCCGAGGGCGTGGGC
GCCGTGCTGCTCAAGCCGCTGGCCCGCGCGCTGGCCGACGACGACC
GGATCCTGGCGGTGATCAAAGCCTCCTCGGTCAACCACGGCGGCCG
CGCGACCGGCTACTACGCGCCGAACGCGAACGCCCAGGTCGACCTGA
TGGAGGCCAGCTTCCGCAAGGCCGGCGTGTCGCCCGAGTCGATCGA
CTACATCGAGGCCGCCGCCAACGGCACCAGCCTCGGCGACGCGGTCG
AGCTGCGCGCGCTGGCGCGCGTGTTCGACGGCACCGCGCGCGACGG
CCGGCGCGTGCCGATCGGCACTGTGAAGTCGAACATCGGCCATCCCG
AGGCGGCCTCGGGCATCGCGCAACTGACCAAGGTGATCCTGCAGAT
GCAGCACGAGACGCTGGTGCCCTCGATCAAGACCGAGCCCGTCAACC
CCAACCTCGACCTGGCCCACACGCCGTTCCGCCTGCTCTCGCGGCAG
GCGGCCTGGCCGTCCGATCCGGCGCGGCCGCGGCGCGCCACGGTCA
GCTCGTTCGGCGCGAGCGGCGCGAACGCGCACCTGATCGTCGAGGC
CTTCGAGACGGTCGAGGCGGAGCCCGCGCCAGCCGTCGCGCAAGCG
GCGCCGCCGGCCGAGATCGTGGTGCTGTCGGCGCGCACGCCGGCTC
AGTTGCGCGAGGTGGCGCGGCGCCTGCTGGCCTGGCTCGCCACGCG
GCAGGCGGCGGGCAGGGCGGAATCGGCGGTGCCGCTGGCCGAGCGC
GGCCGCGCCTGCTCGCTCGCGAATCTCGCGCACACGCTGCAGATCGG
GCGCGAGGCGATGGACTGCCGGCTCGCGCTGCTGGCCGACAGCCTC
GACACGCTTGGCGATGGCCTGCGGCGTTTCCTCGGCGAATCGGCCG
GCGCGGCCGAGCCCGCGATCTACCACGGCAACGTGCAGGACCAGCT
111
CGAGATGCGCAACCTGCTGGCGGGCGCCGCCGGCGACGCGATGGCG
CAGACCCTGGTGGCCGAACGCAACCTGGAGGGGCTGATGCTGCACT
GGGTCCAGGGCGGCAACGTGCCCTGGGCCGCCCTGCGCGAGGGCCG
GCCGGCGCGCCGCCTGGTGCTGCCGACCTATCCGTTCGAGCGCGAG
CGCTACTGGCTGTCCGGCGCGAGCGACGCCGCGGGCCGCGGCGCGG
GCGAGCCGCAGGTCCCTGCCGAGCCGGCCGAGGCGGCCAGCGAACC
CAGTGTCGTCGATGGGCGGGCCTGA
>Bamb 5917 PCP-COM2C aa
MHHHHHHGKPIPNPLLGLDSTENLYFQGIDPFTGAAAGVSAAGIEPDLTA
IWQALFALPAVGRHQDFFALGGDSQLGLRMLAQLRERHGVDLPLRCLYE
APTVARLAETIVRLAAPAPSGDQDDASEYEEGVIR
>Bamb 5917 PCP-COM2C dna
ATGCATCATCACCATCACCATGGTAAGCCTATCCCTAACCCTCTCCT
CGGTCTCGATTCTACGGAAAACCTGTATTTTCAGGGAATTGATCCCT
TCACCGGCGCCGCCGCGGGCGTCTCGGCGGCCGGCATCGAGCCTGA
CCTGACGGCGATCTGGCAGGCGCTGTTCGCCCTGCCGGCGGTTGGC
CGCCACCAGGATTTCTTCGCGCTCGGCGGCGATTCGCAGCTGGGCCT
GCGCATGCTGGCCCAGCTGCGTGAGCGCCACGGCGTCGACCTGCCG
CTGCGTTGCCTCTACGAGGCGCCCACCGTCGCCCGCCTGGCCGAGAC
GATCGTGCGGCTCGCGGCGCCGGCGCCTTCGGGCGACCAGGACGAT
GCATCGGAGTACGAAGAAGGCGTGATCCGCTGA
>Bamb 5915 C aa
MHHHHHHGKPIPNPLLGLDSTENLYFQGIDPFTMTIPALLSELQARGITLS
LADGELSFRAPKGALTPADRATLSARREAIVAYLAAKAARRTDPVTITPS
AELRPSLLQELWWHWYGLPPRQLNQERLPLVKLFPGVTAGRVAEALRA
IVARHHTLRSSFHEEDGRLTVTLNEAAALPIEFVEADGTLPREELEPALK
AQAAEYAARQLPLDGQWLLRARVVSLAPDQSLLLCVFHHIIVDAASLLLIL
AELDARLADPPRALPAAAQFLDYAAWERAWMADPARQPLIDYWARRF
RALPELVGPLTGRSLAWQPGSKVDHRFVIPAAQLRRMQAAATRLQTSLF
SALLSAFGVALARWSGSERVPVRCVGDLRTSPELANLVGYLVCSDVIEIH
APAKADFVSILKASEIESHSAMMLRVPTLMRHPLHRGGSGIEDPRGIAATI
NMFSVRIPGAGAPLDERADPPWPPQLTRSAGEPWPIPLPSIYLRLIDYGH
ALEGSLELNDTLLTAAEQAALIEALFDALDRFLLQAAPAAAPLTTEVL
>Bamb 5915 C dna
ATGCATCATCACCATCACCATGGTAAGCCTATCCCTAACCCTCTCCT
CGGTCTCGATTCTACGGAAAACCTGTATTTTCAGGGAATTGATCCCT
TCACCATGACGATTCCCGCCTTGCTGTCCGAGCTGCAGGCGCGCGGC
ATCACGCTGTCCCTGGCCGATGGCGAGCTGTCGTTCCGCGCGCCCAA
GGGCGCGTTGACGCCGGCCGATCGCGCGACGCTGTCGGCGAGGCGC
GAAGCGATCGTTGCCTACCTGGCCGCCAAGGCCGCGCGCCGCACCGA
TCCGGTGACGATCACGCCCTCGGCCGAGCTGCGTCCCTCGCTGCTCC
AGGAACTCTGGTGGCACTGGTACGGCCTGCCGCCGCGCCAGCTGAA
CCAGGAGCGCCTGCCGCTCGTCAAGCTGTTCCCGGGCGTGACGGCC
GGGCGCGTGGCCGAGGCGCTGCGCGCCATCGTGGCCCGCCACCACA
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CGCTGCGCTCCTCGTTCCATGAAGAGGACGGCCGGCTGACCGTCACG
CTCAACGAAGCCGCGGCGCTGCCGATCGAGTTCGTCGAGGCCGACG
GCACGCTGCCGCGCGAGGAGCTGGAGCCCGCGCTGAAAGCGCAGGC
GGCCGAGTATGCCGCGCGCCAGCTGCCGCTCGACGGGCAGTGGCTG
CTGCGCGCGCGCGTCGTCTCGCTGGCGCCCGACCAGAGCCTGCTGCT
GTGCGTGTTCCATCACATCATCGTCGACGCGGCCTCGCTGCTGCTGA
TCCTCGCCGAGCTCGACGCGCGGCTGGCCGATCCGCCGCGCGCGCTG
CCAGCCGCCGCGCAGTTCCTCGACTACGCGGCCTGGGAGCGGGCCT
GGATGGCCGATCCCGCGCGTCAGCCGTTGATCGACTACTGGGCGCG
GCGCTTTCGCGCGCTGCCCGAGCTGGTCGGCCCGCTCACGGGTCGCT
CGCTGGCCTGGCAGCCGGGCAGCAAGGTCGACCATCGCTTCGTGAT
TCCGGCCGCGCAGCTGCGCCGCATGCAGGCCGCCGCCACGCGCCTGC
AGACCTCGCTCTTCAGCGCGCTGCTGAGCGCCTTCGGCGTGGCGCTG
GCGCGCTGGTCCGGCAGCGAGCGGGTGCCGGTGCGCTGCGTCGGCG
ACCTGCGCACCTCGCCCGAGCTGGCGAACCTCGTCGGTTACCTGGTC
TGCAGCGACGTGATCGAGATCCACGCGCCGGCCAAGGCCGATTTCG
TGTCGATCCTGAAGGCCAGCGAGATCGAATCGCACAGCGCGATGAT
GCTGCGCGTGCCGACCCTGATGCGCCATCCGCTGCACCGGGGCGGC
AGCGGCATCGAGGATCCGCGCGGCATCGCGGCCACCATCAACATGT
TCTCGGTGCGCATCCCCGGCGCCGGCGCGCCGCTCGACGAGCGCGC
CGATCCGCCCTGGCCGCCGCAGCTGACGCGCTCGGCCGGCGAGCCCT
GGCCGATTCCCTTGCCGTCGATCTACCTGCGGCTGATCGATTACGGC
CACGCGCTGGAAGGTTCGCTGGAACTCAACGACACGCTGCTGACGG
CCGCCGAGCAGGCCGCGCTGATCGAGGCGCTGTTCGATGCGCTCGA
CCGCTTCCTGCTGCAGGCCGCGCCGGCGGCGGCGCCCCTCACCACGG
AGGTTTTATGA
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7.2 Protein NMR spectroscopy bu↵er screening
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Figure 7.1: HSQC of PCP screening bu↵er pH from 7.0 (blue) to 5.5 (red).
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Figure 7.2: Chemical shift perturbations of PCP from pH 6 to 7.
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Figure 7.3: HSQC of PCP screening temperature from 10  C (blue) to 25  C
(red), referenced using DSS.
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Figure 7.4: Temperature from pH 6 to 7. Values above dashed line are proposed
to be involved in H-bonding.
Table 7.1: Chemical shift assignments for PCP-COM2C (in collaboration with
Dr Angelo Gallo).
Residue number Residue type Atom label Chemical shift
(ppm)
1 GLY H1 8.067
1 GLY N 110.713
1 GLY C 173.714
1 GLY CA 45.48
1 GLY HA2 3.913
1 GLY HA3 3.851
2 ALA C 177.365
2 ALA CA 52.714
2 ALA CB 19.273
2 ALA H 8.193
2 ALA HA 4.285
2 ALA QB 1.345
2 ALA N 123.662
3 ALA C 177.497
3 ALA CA 52.665
3 ALA CB 19.389
3 ALA H 8.402
3 ALA HA 4.272
3 ALA QB 1.365
3 ALA N 123.073
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Table 7.1: (continued)
Residue number Residue type Atom label Chemical shift
(ppm)
4 ALA C 178.179
4 ALA CA 52.723
4 ALA CB 19.221
4 ALA H 8.258
4 ALA HA 4.264
4 ALA QB 1.36
4 ALA N 122.841
5 GLY C 174.054
5 GLY CA 45.345
5 GLY H 8.327
5 GLY HA2 3.922
5 GLY HA3 3.881
5 GLY N 108.095
6 VAL C 175.977
6 VAL CA 62.176
6 VAL CB 32.954
6 VAL CG1 21.134
6 VAL CG2 20.753
6 VAL H 8.049
6 VAL HA 4.107
6 VAL HB 2.006
6 VAL QG1 0.839
6 VAL QG2 0.884
6 VAL N 119.898
7 SER C 174.726
7 SER CA 57.979
7 SER CB 64.59
7 SER H 8.446
7 SER HA 4.531
7 SER HB2 3.901
7 SER HB3 3.97
7 SER N 120.116
8 ALA C 178.691
8 ALA CA 54.975
8 ALA CB 18.978
8 ALA H 8.983
8 ALA HA 3.929
8 ALA QB 1.35
8 ALA N 126.735
9 ALA HA 4.035
9 ALA QB 1.322
9 ALA N 119.306
9 ALA C 179.39
9 ALA CA 53.997
9 ALA CB 18.708
9 ALA H 8.297
10 GLY C 174.761
10 GLY CA 45.772
10 GLY H 7.887
10 GLY HA2 3.882
10 GLY HA3 3.921
10 GLY N 104.837
11 ILE C 176.623
11 ILE CA 60.863
11 ILE CB 39.263
11 ILE CD1 13.326
11 ILE CG1 27.074
11 ILE CG2 17.69
11 ILE H 7.754
11 ILE HA 4.171
11 ILE HB 1.744
11 ILE QD1 0.633
11 ILE HG12 1.394
11 ILE HG13 1.366
11 ILE QG2 0.803
11 ILE N 118.79
12 GLU CA 56.503
12 GLU CB 30.209
12 GLU CG 36.411
12 GLU H 7.66
12 GLU HB2 1.946
12 GLU HB3 1.926
12 GLU HG2 2.267
12 GLU HG3 2.261
12 GLU N 114.846
12 GLU C 175.699
12 GLU HA 4.196
13 PRO C 177.145
13 PRO CA 63.354
13 PRO CB 32.096
13 PRO CD 50.925
13 PRO CG 27.059
13 PRO HA 4.428
13 PRO HB2 2.288
13 PRO HB3 2.257
13 PRO HD2 3.799
13 PRO HD3 3.808
13 PRO HG2 1.893
13 PRO HG3 1.912
14 ASP C 177.497
14 ASP CA 56.05
14 ASP CB 41.499
14 ASP H 8.619
14 ASP HB3 2.805
14 ASP HB2 2.53
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Table 7.1: (continued)
Residue number Residue type Atom label Chemical shift
(ppm)
14 ASP N 127.077
14 ASP HA 4.189
15 LEU C 177.849
15 LEU CA 55.161
15 LEU CB 42.299
15 LEU CD1 22.304
15 LEU CD2 22.493
15 LEU CG 26.091
15 LEU H 7.804
15 LEU QD1 0.539
15 LEU QD2 0.541
15 LEU HG 0.666
15 LEU N 121.08
15 LEU HB2 1.49
15 LEU HB3 1.506
15 LEU HA 3.947
16 THR CG2 21.705
16 THR H 8.583
16 THR HA 4.225
16 THR HB 4.881
16 THR QG2 1.187
16 THR N 115.603
16 THR C 175.685
16 THR CA 70.166
16 THR CB 68.405
17 ALA C 181.418
17 ALA CA 55.944
17 ALA CB 18.275
17 ALA H 7.79
17 ALA HA 4.151
17 ALA QB 1.569
17 ALA N 122.169
18 ILE C 178.698
18 ILE CA 65.668
18 ILE CB 38.964
18 ILE CD1 13.797
18 ILE CG1 27.121
18 ILE CG2 18.681
18 ILE H 7.748
18 ILE HA 3.912
18 ILE HB 2.26
18 ILE QD1 0.959
18 ILE HG12 1.563
18 ILE HG13 1.575
18 ILE QG2 1.189
18 ILE N 118.751
19 TRP C 178.029
19 TRP CA 62.441
19 TRP CB 28.781
19 TRP H 9.166
19 TRP HA 4.375
19 TRP HB2 3.439
19 TRP HB3 3.243
19 TRP HE1 8.82
19 TRP N 122.133
19 TRP NE1 120.909
20 GLN C 178.179
20 GLN CA 60.269
20 GLN CB 28.988
20 GLN CG 34.524
20 GLN H 9.232
20 GLN HA 3.888
20 GLN HB2 2.208
20 GLN HB3 2.254
20 GLN HE21 6.844
20 GLN HE22 7.129
20 GLN HG2 2.457
20 GLN HG3 2.471
20 GLN N 118.397
20 GLN NE2 109.445
21 ALA C 180.416
21 ALA CA 54.626
21 ALA CB 18.372
21 ALA H 7.417
21 ALA HA 4.257
21 ALA QB 1.54
21 ALA N 118.88
22 LEU C 178.382
22 LEU CA 57.872
22 LEU CB 42.78
22 LEU CD1 25.211
22 LEU CD2 24.983
22 LEU CG 27.358
22 LEU H 8.134
22 LEU HA 3.895
22 LEU HB2 1.461
22 LEU HB3 1.12
22 LEU QD1 0.601
22 LEU QD2 0.433
22 LEU HG 1.524
22 LEU N 119.625
23 PHE C 174.225
23 PHE CA 58.717
23 PHE CB 40.315
23 PHE H 7.923
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Table 7.1: (continued)
Residue number Residue type Atom label Chemical shift
(ppm)
23 PHE HA 4.395
23 PHE HB2 3.273
23 PHE HB3 2.494
23 PHE N 113.301
24 ALA C 176.118
24 ALA CA 53.289
24 ALA CB 16.497
24 ALA H 7.838
24 ALA HA 4.047
24 ALA QB 1.399
24 ALA N 123.233
25 LEU C 176.453
25 LEU CA 51.244
25 LEU CB 42.153
25 LEU CD1 23.061
25 LEU CD2 25.671
25 LEU CG 26.86
25 LEU H 8.026
25 LEU QD1 0.984
25 LEU QD2 0.874
25 LEU HG 1.603
25 LEU N 118.05
25 LEU HA 5.01
25 LEU HB3 1.496
25 LEU HB2 1.524
26 PRO C 176.12
26 PRO CA 63.454
26 PRO CB 32.095
26 PRO CD 50.962
26 PRO CG 28.951
26 PRO HA 4.326
26 PRO HB2 1.621
26 PRO HB3 1.608
26 PRO HD2 3.853
26 PRO HD3 3.823
26 PRO HG2 2.135
26 PRO HG3 2.119
27 ALA C 175.773
27 ALA CA 51.39
27 ALA CB 21.498
27 ALA H 7.112
27 ALA HA 4.5
27 ALA QB 1.208
27 ALA N 117.162
28 VAL C 175.431
28 VAL CA 61.241
28 VAL CB 35.671
28 VAL CG1 22.881
28 VAL CG2 21.512
28 VAL H 8.252
28 VAL HA 4.164
28 VAL HB 1.885
28 VAL QG1 0.96
28 VAL QG2 1.213
28 VAL N 122.003
29 GLY C 175.944
29 GLY CA 45.161
29 GLY H 9.442
29 GLY HA2 4.144
29 GLY HA3 3.895
29 GLY N 117.106
30 ARG C 173.666
30 ARG CA 58.076
30 ARG CB 32.07
30 ARG CD 43.508
30 ARG CG 27.107
30 ARG H 8.563
30 ARG HA 3.87
30 ARG HB2 1.514
30 ARG HB3 1.64
30 ARG HD2 3.155
30 ARG HD3 3.126
30 ARG HG2 1.816
30 ARG HG3 1.525
30 ARG N 121.74
31 HIS C 176.278
31 HIS CA 54.787
31 HIS CB 31.145
31 HIS H 8.277
31 HIS HA 5.122
31 HIS HB2 3.336
31 HIS HB3 2.834
31 HIS N 113.397
32 GLN C 174.856
32 GLN CA 57.42
32 GLN CB 31.765
32 GLN CG 36.455
32 GLN H 7.4
32 GLN HA 4.282
32 GLN HB2 2.273
32 GLN HB3 2.248
32 GLN HG2 2.275
32 GLN HG3 2.144
32 GLN N 120.086
33 ASP C 175.763
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Table 7.1: (continued)
Residue number Residue type Atom label Chemical shift
(ppm)
33 ASP CA 54.409
33 ASP CB 44.501
33 ASP H 8.745
33 ASP HA 4.877
33 ASP HB2 2.836
33 ASP HB3 2.551
33 ASP N 126.206
34 PHE C 175.427
34 PHE CA 61.873
34 PHE CB 41.895
34 PHE H 9.733
34 PHE HA 4.897
34 PHE HB2 2.824
34 PHE HB3 2.887
34 PHE N 125.94
35 PHE C 180.49
35 PHE CA 60.32
35 PHE CB 39.842
35 PHE H 8.29
35 PHE HA 4.181
35 PHE HB2 3.264
35 PHE HB3 2.884
35 PHE N 116.781
36 ALA C 180.593
36 ALA CA 55.442
36 ALA CB 18.328
36 ALA H 9.196
36 ALA HA 4.178
36 ALA QB 1.596
36 ALA N 129.022
37 LEU C 175.948
37 LEU CA 55.831
37 LEU CB 42.549
37 LEU CD1 26.164
37 LEU CD2 20.974
37 LEU CG 27.415
37 LEU H 7.769
37 LEU HA 3.792
37 LEU HB2 1.476
37 LEU HB3 1.585
37 LEU QD1 0.943
37 LEU QD2 0.498
37 LEU HG 1.459
37 LEU N 116.96
38 GLY C 175.077
38 GLY CA 44.285
38 GLY H 7.527
38 GLY HA2 4.341
38 GLY HA3 3.641
38 GLY N 103.697
39 GLY C 169.934
39 GLY CA 46.461
39 GLY H 8.188
39 GLY HA2 3.582
39 GLY HA3 3.563
39 GLY N 109.603
40 ASP C 176.758
40 ASP CA 52.462
40 ASP CB 42.617
40 ASP H 6.995
40 ASP HB2 2.865
40 ASP HB3 3.523
40 ASP N 118.086
40 ASP HA 5.092
41 SER C 175.453
41 SER CA 62.944
41 SER CB 62.415
41 SER H 9.127
41 SER HA 4.899
41 SER HB2 4.193
41 SER HB3 4.112
41 SER N 115.321
42 GLN C 179.498
42 GLN CA 59.51
42 GLN CB 28.433
42 GLN CG 34.589
42 GLN H 7.96
42 GLN HA 4.07
42 GLN HB2 2.132
42 GLN HB3 2.236
42 GLN HG2 2.459
42 GLN HG3 2.384
42 GLN N 120.912
43 LEU C 179.724
43 LEU CA 58.323
43 LEU CB 42.68
43 LEU CD1 24.62
43 LEU CD2 25.467
43 LEU CG 27.163
43 LEU H 9.064
43 LEU HA 4.023
43 LEU HB2 1.708
43 LEU HB3 1.487
43 LEU QD1 0.778
43 LEU QD2 0.269
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Table 7.1: (continued)
Residue number Residue type Atom label Chemical shift
(ppm)
43 LEU HG 1.57
43 LEU N 123.543
44 GLY C 174.746
44 GLY CA 48.319
44 GLY H 9.053
44 GLY N 107.893
44 GLY HA3 3.143
44 GLY HA2 3.177
45 LEU CB 42.606
45 LEU CA 60.197
45 LEU C 178.7
45 LEU HA 3.709
45 LEU H 8.48
45 LEU QB 1.647
45 LEU N 119.16
45 LEU CG 27.366
45 LEU CD1 27.211
45 LEU CD2 26.5
45 LEU HG 1.567
45 LEU QD1 0.896
45 LEU QD2 0.844
46 ARG C 177.674
46 ARG CA 56.894
46 ARG CB 30.279
46 ARG CD 43.378
46 ARG CG 27.25
46 ARG H 8.698
46 ARG HA 4.203
46 ARG HB2 1.953
46 ARG HB3 1.924
46 ARG HD2 3.154
46 ARG HD3 3.113
46 ARG HG2 1.604
46 ARG HG3 1.563
46 ARG N 115.649
48 LEU C 176.974
48 LEU CA 58.552
48 LEU CB 42.132
48 LEU CD1 24.85
48 LEU CD2 24.17
48 LEU CG 27.287
48 LEU HB2 1.504
48 LEU HB3 1.527
48 LEU QD1 0.853
48 LEU QD2 0.786
48 LEU HG 1.107
48 LEU HA 3.917
49 ALA H 7.38
49 ALA N 118.862
49 ALA C 175.776
49 ALA CA 57.76
49 ALA CB 18.166
49 ALA HA 4.251
49 ALA QB 1.551
50 GLN C 179.56
50 GLN CA 60.209
50 GLN CG 34.59
50 GLN H 8.007
50 GLN HA 4.087
50 GLN HB2 1.933
50 GLN HB3 1.691
50 GLN HG2 2.384
50 GLN HG3 2.366
50 GLN N 119.738
50 GLN CB 29.54
51 LEU C 180.421
51 LEU CA 58.793
51 LEU CB 42.534
51 LEU CD1 24.716
51 LEU CD2 25.244
51 LEU CG 27.009
51 LEU H 9.068
51 LEU QD1 0.773
51 LEU QD2 0.273
51 LEU HG 1.596
51 LEU N 123.409
51 LEU HA 4.074
51 LEU HB2 1.929
51 LEU HB3 1.542
52 ARG C 178.524
52 ARG CA 59.162
52 ARG CB 30.248
52 ARG CD 43.601
52 ARG CG 27.091
52 ARG H 7.82
52 ARG HA 4.085
52 ARG HB2 1.901
52 ARG HB3 1.963
52 ARG HD2 3.133
52 ARG HD3 3.143
52 ARG HG2 0.947
52 ARG HG3 1.551
52 ARG N 120.974
53 GLU C 178.195
53 GLU CA 59.022
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Residue number Residue type Atom label Chemical shift
(ppm)
53 GLU CB 30.848
53 GLU CG 36.08
53 GLU H 8.57
53 GLU HB2 1.846
53 GLU HB3 1.943
53 GLU HG2 2.229
53 GLU HG3 2.241
53 GLU N 121.236
53 GLU HA 3.867
54 ARG C 177.66
54 ARG CA 58.292
54 ARG CB 29.978
54 ARG CD 41.562
54 ARG CG 27.25
54 ARG H 8.341
54 ARG HD2 3.002
54 ARG HD3 3.018
54 ARG HG2 1.563
54 ARG HG3 1.602
54 ARG N 114.593
54 ARG HA 4.052
54 ARG HB2 2.045
54 ARG HB3 2.11
55 HIS C 175.962
55 HIS CA 55.997
55 HIS CB 31.49
55 HIS H 7.792
55 HIS HA 4.898
55 HIS HB2 3.2
55 HIS HB3 2.893
55 HIS N 112.431
56 GLY C 173.542
56 GLY CA 47.099
56 GLY H 7.984
56 GLY HA2 4.057
56 GLY HA3 3.888
56 GLY N 109.208
57 VAL C 173.57
57 VAL CA 61.476
57 VAL CB 33.774
57 VAL CG1 21.115
57 VAL CG2 20.868
57 VAL H 6.647
57 VAL HA 4.059
57 VAL HB 1.68
57 VAL QG1 0.825
57 VAL QG2 0.856
57 VAL N 118.368
58 ASP C 174.063
58 ASP CA 52.871
58 ASP CB 42.203
58 ASP H 8.928
58 ASP HA 4.698
58 ASP HB2 2.899
58 ASP HB3 2.252
58 ASP N 129.077
59 LEU CA 57.518
59 LEU CB 42.449
59 LEU CD1 26.44
59 LEU CD2 26.37
59 LEU CG 31.378
59 LEU H 8.754
59 LEU QD1 0.788
59 LEU QD2 0.804
59 LEU HG 1.453
59 LEU N 125.028
59 LEU C 174.232
59 LEU HA 4.72
59 LEU QB 1.692
60 PRO C 177.251
60 PRO CA 61.423
60 PRO CB 32.435
60 PRO CD 50.23
60 PRO CG 27.628
60 PRO HA 4.565
60 PRO HB2 2.272
60 PRO HB3 2.13
60 PRO HD2 3.616
60 PRO HD3 3.795
60 PRO HG2 2.053
60 PRO HG3 2.002
61 LEU C 178.762
61 LEU CA 58.434
61 LEU CB 41.648
61 LEU CD1 21.484
61 LEU CD2 23.336
61 LEU CG 27.345
61 LEU H 8.46
61 LEU HA 4.045
61 LEU HB2 1.505
61 LEU HB3 1.527
61 LEU QD1 0.832
61 LEU QD2 0.899
61 LEU HG 1.463
61 LEU N 121.866
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Table 7.1: (continued)
Residue number Residue type Atom label Chemical shift
(ppm)
62 ARG C 176.644
62 ARG CA 60.973
62 ARG CB 31.827
62 ARG CD 43.619
62 ARG CG 27.25
62 ARG H 8.625
62 ARG HA 4.169
62 ARG HB2 1.766
62 ARG HB3 1.646
62 ARG HD2 3.191
62 ARG HD3 3.231
62 ARG HG2 1.571
62 ARG HG3 1.606
62 ARG N 115.716
63 CYS C 178.35
63 CYS CA 63.505
63 CYS CB 27.895
63 CYS H 7.904
63 CYS HA 4.111
63 CYS HB3 2.718
63 CYS N 115.28
63 CYS HB2 2.913
64 LEU C 176.973
64 LEU CA 57.422
64 LEU CB 43.349
64 LEU CD1 22.751
64 LEU CD2 26.003
64 LEU CG 26.505
64 LEU H 7.59
64 LEU HA 4.135
64 LEU HB2 1.001
64 LEU HB3 1.028
64 LEU QD1 0.392
64 LEU QD2 -0.291
64 LEU HG 1.019
64 LEU N 119.43
65 TYR C 178.889
65 TYR CA 61.578
65 TYR CB 38.913
65 TYR H 7.092
65 TYR HA 4.159
65 TYR HB2 2.899
65 TYR HB3 2.995
65 TYR N 114.368
66 GLU C 175.791
66 GLU CA 57.106
66 GLU CB 30.066
66 GLU CG 36.294
66 GLU H 7.727
66 GLU HA 4.124
66 GLU HB2 2.116
66 GLU HB3 1.926
66 GLU HG2 2.296
66 GLU HG3 2.29
66 GLU N 115.187
67 ALA CA 50.403
67 ALA CB 18.955
67 ALA H 7.525
67 ALA N 123.657
67 ALA C 172
67 ALA HA 4.626
67 ALA QB 1.199
68 PRO C 176.283
68 PRO CA 64.699
68 PRO CB 29.413
68 PRO CD 50.795
68 PRO CG 27.002
68 PRO HA 4.88
68 PRO HB2 2.238
68 PRO HB3 2.278
68 PRO HD2 3.849
68 PRO HD3 3.747
68 PRO HG2 1.92
68 PRO HG3 1.993
69 THR C 173.541
69 THR CA 58.885
69 THR CB 72.072
69 THR CG2 22.137
69 THR H 7.49
69 THR HA 5.223
69 THR HB 4.941
69 THR QG2 1.066
69 THR N 109.086
70 VAL C 177.642
70 VAL CA 67.695
70 VAL CB 31.614
70 VAL CG1 20.858
70 VAL CG2 21.466
70 VAL H 9.863
70 VAL HA 2.759
70 VAL HB 1.47
70 VAL QG1 0.494
70 VAL QG2 -0.4
70 VAL N 125.007
71 ALA C 181.623
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Residue number Residue type Atom label Chemical shift
(ppm)
71 ALA CA 55.761
71 ALA CB 18.598
71 ALA H 8.668
71 ALA HA 3.829
71 ALA QB 1.12
71 ALA N 118.558
72 ARG C 179.378
72 ARG CA 61.435
72 ARG CB 30.038
72 ARG CD 43.942
72 ARG CG 27.25
72 ARG H 8.066
72 ARG HA 4.1
72 ARG HB2 1.94
72 ARG HB3 2.008
72 ARG HD2 3.152
72 ARG HD3 3.192
72 ARG HG2 1.516
72 ARG HG3 1.535
72 ARG N 116.205
73 LEU C 178.903
73 LEU CA 58.268
73 LEU CB 41.709
73 LEU CD1 23.93
73 LEU CD2 21.918
73 LEU CG 26.86
73 LEU H 9.616
73 LEU HA 4.071
73 LEU HB2 1.611
73 LEU HB3 1.644
73 LEU QD1 0.892
73 LEU QD2 0.804
73 LEU HG 1.881
73 LEU N 126.772
74 ALA C 178.827
74 ALA CA 55.473
74 ALA CB 19.266
74 ALA H 8.608
74 ALA HA 3.817
74 ALA QB 1.41
74 ALA N 120.544
75 GLU C 178.884
75 GLU CA 59.5
75 GLU CB 29.656
75 GLU CG 36.398
75 GLU H 7.133
75 GLU HA 3.928
75 GLU HB2 2.113
75 GLU HB3 2.083
75 GLU HG2 2.223
75 GLU HG3 2.203
75 GLU N 115.585
76 THR C 175.447
76 THR CA 67.079
76 THR CB 68.924
76 THR CG2 21.505
76 THR H 7.899
76 THR HA 3.84
76 THR HB 4.503
76 THR QG2 1.229
76 THR N 117.929
77 ILE C 177.794
77 ILE CA 64.451
77 ILE CB 36.447
77 ILE CD1 18.27
77 ILE CG1 27.265
77 ILE CG2 18.914
77 ILE H 8.109
77 ILE HA 3.888
77 ILE HB 2.051
77 ILE QD1 1.195
77 ILE HG12 1.656
77 ILE HG13 1.518
77 ILE QG2 1.124
77 ILE N 121.307
78 VAL C 178.36
78 VAL CA 65.69
78 VAL CB 32.045
78 VAL CG1 22.909
78 VAL CG2 21.465
78 VAL H 7.924
78 VAL HA 3.606
78 VAL HB 2.113
78 VAL QG1 0.968
78 VAL QG2 0.928
78 VAL N 118.038
79 ARG C 178.54
79 ARG CA 59.253
79 ARG CB 30.15
79 ARG CD 43.505
79 ARG CG 27.129
79 ARG H 7.873
79 ARG HA 4.097
79 ARG QB 1.924
79 ARG HD2 3.202
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79 ARG HD3 3.192
79 ARG HG2 1.824
79 ARG HG3 1.854
79 ARG N 119.615
80 LEU C 177.83
80 LEU CA 56.483
80 LEU CB 39.032
80 LEU CD1 26.397
80 LEU CD2 24.552
80 LEU CG 27.641
80 LEU H 7.967
80 LEU HA 4.209
80 LEU HB2 1.743
80 LEU HB3 1.938
80 LEU QD1 0.819
80 LEU QD2 0.774
80 LEU HG 1.58
80 LEU N 118.439
81 ALA C 176.98
81 ALA CA 52.667
81 ALA CB 19.26
81 ALA H 7.73
81 ALA HA 4.277
81 ALA QB 1.416
81 ALA N 121.635
82 ALA C 175.079
82 ALA CA 50.806
82 ALA CB 18.394
82 ALA H 7.77
82 ALA N 123.696
82 ALA HA 4.556
82 ALA QB 1.348
83 PRO C 176.462
83 PRO CA 62.951
83 PRO CB 31.847
83 PRO CD 50.694
83 PRO CG 27.397
83 PRO HA 4.431
83 PRO HB2 1.891
83 PRO HB3 1.861
83 PRO HD2 3.799
83 PRO HD3 3.608
83 PRO HG2 2.005
83 PRO HG3 1.99
84 ALA C 175.597
84 ALA CA 50.575
84 ALA CB 18.812
84 ALA H 8.544
84 ALA N 125.926
84 ALA HA 4.559
84 ALA QB 1.378
85 PRO C 176.974
85 PRO CA 62.754
85 PRO CB 32.097
85 PRO CD 50.593
85 PRO CG 27.274
85 PRO HA 4.427
85 PRO HB2 1.879
85 PRO HB3 2.271
85 PRO HD2 3.615
85 PRO HD3 3.784
85 PRO HG2 2.001
85 PRO HG3 2.047
86 SER C 175.327
86 SER CA 58.631
86 SER CB 64.28
86 SER H 8.6
86 SER HA 4.426
86 SER HB2 3.895
86 SER HB3 3.914
86 SER N 116.735
87 GLY C 173.897
87 GLY CA 45.512
87 GLY H 8.53
87 GLY HA2 3.967
87 GLY HA3 3.994
87 GLY N 110.977
88 ASP C 175.771
88 ASP CA 54.573
88 ASP CB 41.269
88 ASP H 8.279
88 ASP HA 4.548
88 ASP HB2 2.696
88 ASP HB3 2.617
88 ASP N 122.061
89 GLN C 175.509
89 GLN CA 55.722
89 GLN CB 29.331
89 GLN CG 33.948
89 GLN H 8.463
89 GLN HA 4.305
89 GLN HB2 1.957
89 GLN HB3 2.119
89 GLN HE21 6.562
89 GLN HE22 7.327
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89 GLN HG2 2.338
89 GLN HG3 2.313
89 GLN N 120.265
89 GLN NE2 108.786
90 ASP C 176.286
90 ASP CA 54.544
90 ASP CB 41.368
90 ASP H 8.364
90 ASP HA 4.872
90 ASP HB2 2.676
90 ASP HB3 2.595
90 ASP N 120.407
91 ASP C 176.128
91 ASP CA 54.559
91 ASP CB 41.406
91 ASP H 8.373
91 ASP HA 4.562
91 ASP HB2 2.681
91 ASP HB3 2.583
91 ASP N 121.152
92 ALA C 178.02
92 ALA CA 52.731
92 ALA CB 19.199
92 ALA H 8.351
92 ALA HA 4.275
92 ALA QB 1.355
92 ALA N 124.781
93 SER C 174.737
93 SER CA 59.205
93 SER CB 64.086
93 SER H 8.36
93 SER HA 4.332
93 SER HB2 3.804
93 SER HB3 3.84
93 SER N 115.307
94 GLU C 176.126
94 GLU CA 56.475
94 GLU CB 30.791
94 GLU CG 36.417
94 GLU H 8.407
94 GLU HA 4.199
94 GLU HB2 1.836
94 GLU HB3 1.925
94 GLU HG2 2.08
94 GLU HG3 2.148
94 GLU N 122.316
95 TYR C 175.604
95 TYR CA 57.943
95 TYR CB 39.082
95 TYR H 8.16
95 TYR HA 4.517
95 TYR HB2 2.897
95 TYR HB3 2.993
95 TYR N 120.721
96 GLU C 175.951
96 GLU CA 56.449
96 GLU CB 30.519
96 GLU CG 36.467
96 GLU H 8.262
96 GLU HA 4.203
96 GLU HB2 1.938
96 GLU HB3 1.854
96 GLU HG2 2.181
96 GLU HG3 2.2
96 GLU N 123.573
97 GLU C 177.152
97 GLU CA 57.318
97 GLU CB 30.223
97 GLU CG 36.427
97 GLU H 8.526
97 GLU HA 4.13
97 GLU HB2 1.951
97 GLU HB3 2.006
97 GLU HG2 2.26
97 GLU HG3 2.277
97 GLU N 122.867
98 GLY C 173.876
98 GLY CA 45.433
98 GLY H 8.577
98 GLY HA2 3.919
98 GLY HA3 3.886
98 GLY N 110.376
99 VAL C 175.777
99 VAL CA 62.631
99 VAL CB 32.023
99 VAL CG1 21.138
99 VAL CG2 21.138
99 VAL H 7.824
99 VAL HA 4.046
99 VAL HB 1.919
99 VAL QG1 0.841
99 VAL QG2 0.843
99 VAL N 119.904
100 ILE C 175.248
100 ILE CA 62.055
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Residue number Residue type Atom label Chemical shift
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100 ILE CB 38.294
100 ILE CD1 12.716
100 ILE CG1 27.574
100 ILE CG2 17.647
100 ILE H 8.409
100 ILE HA 4.047
100 ILE HB 1.798
100 ILE QD1 0.794
100 ILE HG12 1.137
100 ILE HG13 1.154
100 ILE QG2 0.86
100 ILE N 126.7
101 ARG C 180.817
101 ARG CA 58.299
101 ARG CB 31.713
101 ARG CD 43.679
101 ARG CG 27.25
101 ARG H 8.118
101 ARG HD2 3.209
101 ARG HD3 3.178
101 ARG HG2 1.567
101 ARG HG3 1.51
101 ARG N 131.766
101 ARG HB2 1.774
101 ARG HB3 1.642
101 ARG HA 4.136
7.3 dd-containing biosynthetic pathways
7.3.1 Natural products from biosynthetic pathways using
dd2 domains
Aculeximycin, Akaeolide, Ansamitocin, Apoptolidin, Bafilomycin, Barbamide,
BE-14106, Calcimycin, Chalcomycin, Chaxamycin, Chlorothricin, Concanamycin,
Coronafacic, Cremimycin, Dihydrochalcomycin, Divergolide, E-837, Ebelactone,
Elaiophylin, FK520, Halstoctacosanolide, Herbimycin, Herboxidiene, Hitachimycin,
Hygrocin, Incednine, Indanomycin, Kendomycin, Kijanimicin, Lasalocid, Leu-
canicidin, Lipomycin, Lobophorin, Lorneic, Macbecin, Meilingmycin, Methymycin,
ML-449, Mycinamicin, Nanchangmycin, Naphthomycin, Natamycin, Nemadectin,
Neoaureothin, Niddamycin, Nystatin, Nystatin-like, Piericidin, Pimaricin, Pla-
dienolide, Polyoxypeptin, Reveromycin, Rifamycin, Rubradirin, Salinomycin, San-
glifehrin, Spinosad, Spirangien, Stambomycin, Streptolydigin, Tautomycin, Tetro-
carcin, Tiacumicin, Tirandamycin, Tylactone, Versipelostatin.
7.3.2 Natural products from biosynthetic pathways using
dd3 domains
Ambruticin, Anatoxin, Aurafuron, Bacillaene, Chlorizidine, Crocacin, Cylindros-
permopsin, Enacyloxin, FK228, Gobichelin, Gulmirecin, JBIR-34, Jerangolid,
Microsclerodermins, Nannocystin, Nostophycin, Oxazolomycin, Pellasoren, Pyralomicin,
Spiruchostatin, Stigmatellin, Tetronomycin.
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pseudomonas
burkholderia
myxococcus
yersinia
anabaena
clostridium
cyanothece
nocardiopsis nostoc
alteromonas
acaryochloris
calothrix
corynebacterium
stigmatella
chamaesiphon chroococcidiopsis
gloeocapsa
microcoleus
ruminococcus
sorangium
streptomyces
azospirillum
clavibacter
desulfitobacterium eggerthella
hahella herpetosiphon
microcystis
staphylococcus
streptococcus
xenorhabdus
actinoplanes actinosynnema alcanivorax
anaerococcus bradyrhizobium
ceratitis
crinalium
cylindrospermum
desulfotomaculum
haliangium legionella
methylophaga mycobacterium
nocardia
nonlabens opitutus
oscillatoria paenibacillus pantoea photorhabdus propionibacterium
rivularia
saccharothrix salinispora shewanella
stanieria
streptosporangium teredinibacter tistrella trichodesmium verrucosispora
Figure 7.5: Word cloud of genera from Atlas PKS/NRPS database that con-
tain COM2N domains, where font size corresponds to the number of occurrence
(created using http://tagcrowd.com).
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7.4 COM2N example biosynthetic genes
C fkbH CP
C A CP C A CP
C A CP
Thr Arg
Ser
A CP C A CP
Val Arg
fkbH
S
O
HO
O
CP
SH
fkbH
SH
O
OH
O
CP
SH
O P O
OH
O-
P
OH
O
O-
PHO
O
O-
fkbH
S
O
HO
HO
CP
SH
fkbH
SH
CP
S
O
HO
HO
e.g. tetronomycin fkbH
kinase
Cyanothece sp. PCC 8801
Figure 7.6: Example COM2-boundary: Cyanothece (WP 012596902.1).
?KS CP
Calothrix sp. PCC 7103
unknown function
Figure 7.7: Example COM2-boundary: Calothrix
C C A CP
C A CP
?
?
KS AT KR CPDH ER
KS AT KR CP
Hyphomonas oceanitis
COM2C genes COM2N genes
Figure 7.8: Example COM2-boundary: Hyphomonas (WP 051624978.1).
A CP Cy CP TEMT?
CCys
...
Finegoldia magna
gastrointestinal and genitourinary flora
Figure 7.9: Example COM2-boundary: Finegoldia (WP 002841792.1).
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dcl
EA CP C?
Microcystis aeruginosa PCC 7941
Leu
Binding partner unclear - potential hypothetical protein
Figure 7.10: Example COM2-boundary: Microcystis
dcl
?
C A CPCP C A CPcal
C C A CP C C A CP
C C A CP C A CP C A CP C C A CP TE
EC A CP C A CP
C C A CP C CP C A CP
lcl lcl
lcl dcl lcl dcl
lcl s lcl lcl lcl s
lcl
lcl s lcl lcl
A CP
dclIle Leu
Thr
Phe
Gamma proteobacterium HdN1
uncharacterised - poor Adenylation substrate prediction
?
E C
Figure 7.11: Example COM2-boundary: Gamma proteobacterium HdN1
(WP 013261592.1).
??
C A CP
MT
C A CP C A CP
??
A CP
C A CP C A CPKS ATMT CP TE
Thr MePro Phe
mal Phe
Nostoc sp. NIES 3756
cluster uncharacterised
Figure 7.12: Example COM2-boundary: Nostoc (WP 067768737.1).
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C A CP TR(βL)...
Crocosphaera watsonii
cluster uncharacterised - poor sequencing
Figure 7.13: Example COM2-boundary: Crocosphaera (WP 007303634.1).
A CP
Bradyrhizobium sp. ARR65
uncharacterised
TE
Figure 7.14: Example COM2-boundary: Bradyrhizobium (WP 024513186.1).
7.4.1 COM2N proteins from Atlas PKS/NRPS database
AAF19812.1, AAY37654.1, AAY91421.3, AAY92759.1, ABA21236.1, ABA51274.1,
ABA74009.1, ABC29733.1, ABC29735.1, ABE54463.1, ABF86893.1, ABF90173.1,
ABF90459.1, ABF92546.1, ABF92546.1, ABG19543.1, ABG52864.1, ABN93222.1,
ABN93233.1, ABP55261.1, ABS45963.1, ABW31348.1, ABW31348.1, ABW31350.1,
ABW31356.1, ABX04504.1, ABX04731.1, ACB52391.1, ACB75253.1, ACC81024.1,
ACC84845.1, ACC85408.1, ACK67008.1, ACK67644.1, ACL21978.1, ACL76665.1,
ACR31662.1, ACV01940.1, ACV02548.1, ACV29783.1, ACY61368.1, ADC88013.1,
ADO71805.1, ADU21412.1, ADU72106.1, ADV97464.1, AEB42527.1, AEI63747.1,
AEO73201.1, AEX42750.1, AEX46387.1, AEX68229.1, AEX72947.1, AEY65152.1,
AEY66938.1, AFI69976.1, AFJ01561.1, AFK57214.1, AFN46007.1, AFT70785.1,
AFW93815.1, AFY33172.1, AFY80136.1, AFY88055.1, AFY89103.1, AFY89103.1,
AFY92098.1, AFZ14010.1, AFZ26071.1, AFZ33016.1, AFZ33307.1, AFZ36194.1,
AFZ59099.1, AFZ60772.1, AFZ60782.1, AFZ60782.1, AGC45618.1, AGC46260.1,
AGC47284.1, AGC47287.1, AGI79641.1, AGL83959.1, AGL85301.1, AGP37466.1,
AGP37474.1, AGP40742.1, AGP88177.1, BAG05480.1, BAG05822.1, BAI74310.1,
BAK43323.1, BAK92291.1, CAE15905.1, CAH22534.1, CAH39107.1, CAH39108.1,
CAK15504.1, CAN00352.1, CAW25429.1, CAW93975.1, CAY48789.1, CBG67371.1,
CBJ11325.1, CBL44580.1, CBL45097.1, CBL45102.1, CBL45103.1, CCC86198.1,
CCE74273.1, CCH32769.1, EAU66331.1,
NP 252915.1, NP 486681.1, NP 486682.1, NP 792634.1, NP 962675.1, NP 994709.1,
XP 004532053.1, YP 001061877.1, YP 001076246.1, YP 001346261.1, YP 001394897.1,
YP 001394901.1, YP 001719506.1, YP 001778907.1, YP 001804456.1, YP 001865727.1,
YP 001866574.1, YP 001873844.1, YP 002345832.1, YP 002373799.1, YP 002471866.1,
YP 002471870.1, YP 002505322.1, YP 002912099.1, YP 003073775.1, YP 003101411.1,
YP 003139384.1, YP 003192079.1, YP 003266191.1, YP 003339432.1, YP 003566894.1,
YP 003678979.1, YP 003678979.1, YP 003678979.1, YP 003678979.1, YP 003678979.1,
YP 003678979.1, YP 003678979.1, YP 003678979.1, YP 003679695.1, YP 003712686.1,
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YP 003712687.1, YP 003844094.1, YP 003954443.1, YP 004664826.1, YP 004664826.1,
YP 004668885.1, YP 004668888.1, YP 004668980.1, YP 004712293.1, YP 004801211.1,
YP 004974482.1, YP 005263991.1, YP 005503890.1, YP 005519936.1, YP 005761026.1,
YP 006269092.1, YP 006277307.1, YP 006278375.1, YP 006480704.1, YP 006657687.1,
YP 006659040.1, YP 006876063.1, YP 006979112.1, YP 006996375.1, YP 007051204.1,
YP 007059070.1, YP 007066010.1, YP 007066010.1, YP 007097198.1, YP 007097198.1,
YP 007121020.1, YP 007121020.1, YP 007121351.1, YP 007130468.1, YP 007137551.1,
YP 007159684.1, YP 007359089.1, YP 007361940.1, YP 007361943.1, YP 007375312.1,
YP 007396976.1, YP 007512510.1, YP 007786329.1, YP 007786384.1, YP 008134859.1,
YP 008174055.1, YP 008174456.1, YP 008198470.1, YP 008327602.1, YP 008500999.1,
YP 110608.1, YP 234878.1, YP 235654.1, YP 273985.1, YP 322128.1, YP 325330.1,
YP 335852.1, YP 347945.1, YP 371431.1, YP 440021.1, YP 519054.1, YP 608605.1,
YP 623238.1, YP 653281.1, YP 777794.1, YP 788894.1, YP 838624.1
7.5 Vibroxin biosynthetic genes
Table 7.2: Proposed functions of genes in the vibroxin biosynthetic gene cluster
based on sequence similarity to genes in the cluster directing enacyloxin biosyn-
thesis in B. ambifaria AMMD
Gene Putative function Homologous
gene
Percent
identity
vbxA FAD dependent oxidoreductase bamb 5928 68
vbxB Aspartyl/Asparaginyl beta-hydroxylase bamb 5927 71
vbxC Thioesterase bamb 5926 45
vbxD beta-ketoacyl synthase bamb 5925 48
vbxE beta-ketoacyl synthase bamb 5924 49
vbxF beta-ketoacyl synthase bamb 5923 46
vbxG beta-ketoacyl synthase bamb 5922 46
vbxH beta-ketoacyl synthase bamb 5921 50
vbxI beta-ketoacyl synthase bamb 5920 47
vbxJ beta-ketoacyl synthase bamb 5919 51
vbxK NADH:flavin oxidoreductase/NADH oxidase bamb 5918 71
vbxL Xylose isomerase domain protein TIM barrel bamb 5912 59
vbxM Shikimate dehydrogenase bamb 5913 53
vbxN Alchohol dehydrogenase, zinc-binding domain bamb 5914 57
vbxO Condensation domain protein bamb 5915 49
vbxP L-carnitine dehydratase/bile acid-inducible bamb 5916 67
vbxQ Phosphopantetheine-binding domain bamb 5917 36
vbxR LuxR transcriptional family regulator bamb 5911 54
vbxS hypothetical protein bamb 5929 51
vbxT MATE e✏ux family protein bamb 5933 55
7.6 NMR spectra for vibroxin
Spectra of 0.3 mg vibroxin were acquired on 500 MHz NMR spectrometer in
d-4MeOH (Fig.7.15-7.19).
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Figure 7.15: 1H spectrum.
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Figure 7.16: COSY spectrum.
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Figure 7.17: 1H-13C HSQC spectrum.
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Figure 7.18: 1H-13C HMBC spectrum
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Figure 7.19: NOESY spectrum with 100 ms mixing time.
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